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Dear colleagues
The current times conspire against the full exercise of Medicine, including clinical and diagnostic 
aspects. The present and future difficulties, of recognized dimensions, present us with a 
challenge.
Effective treatment is founded on accurate diagnosis, the reason and priority of our work.
The determination that animates us is expressed more eloquently in the following words of 
Fernando Pessoa:
“Agir, eis a inteligência verdadeira. Serei o que quiser. Mas tenho que querer o que for. O êxito 
está em ter êxito, e não em ter condições de êxito. Condições de palácio tem qualquer terra 
larga, mas onde estará o palácio se não o fizerem ali?”
Welcome to the first Updating Course on Anatomic Pathology,  Centro Hospitalar do Porto, 2012!
José Ramón Vizcaíno
UPDAtInG CoURse on AnAtoMIC PAtHoLoGY  
CentRo HosPItALAR Do PoRto 2012
organized by
Centro Hospitalar do Porto
serviço de Anatomia Patológica
october 13-16, 2012 – Porto, Portugal
Course Description: We are pleased to announce the 1st edition of our course entitled “Curso de Actualização 
em Anatomia Patológica Centro Hospitalar do Porto 2012”. The course is organized by Centro Hospitalar 
do Porto, Porto [Portugal] and shall provide the highest level of subspecialty instruction by a distinguished 
faculty recognized in the fields of Anatomic Pathology. The educational event shall include 3 days of anatomic 
pathology theoretical and practical sessions related to breast, salivary gland, lymphomas, bone and soft 
tissues, cutaneous melanocytic lesions and pleuropulmonary and mediastinal areas, highlighting diagnostic 
challenges, illustrating potential pitfalls and how to avoid them, and highlighting the role of complementary 
molecular techniques and their application in patient care. The surgical pathology blocks will be anticipated 
by corresponding clinical satellite conferences, giving emphasis on National contributions.
The greatest educational feedback is expected for community hospital physicians, in particular, pathologists 
and residents. The course goal is to provide participants with practical and meaningful information relevant 
to diagnostic task, prognostic assessment and therapy guidance of cancer patients. The course is intended 
for a broad audience; however, it is primarily designed for pathologists devoting most of their efforts to 
practical surgical pathology. Course organizers encourage the participation of anatomic pathology, general 
and thoracic surgery, dermatology, ENT and oncology residents.
Location of the Course: The course will be held in Porto, the second largest city of Portugal, in the west 
coast. It can be reached by airplane through Porto International Airport where various flights are available – 
for more information http://www.ana.pt/en-US/Aeroportos/porto/Porto/Pages/Homepage-Porto.aspx 
Course Venue: Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto.
official language: The surgical pathology course will be taught in English. Simultaneous translation services 
will not be available. The clinical satellite conferences will be lectured in English or Portuguese.
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MeetInG PRoGRAMMe
Saturday, OctOber 13th, 2012
 Registration
 Registration desk will open at 16.00
18:00 – 18:15 Course introduction and welcome to the participants 
  F. Sollari Alllegro, M.D., J.R.Vizcaíno, M.D., R. Henrique, M.D., Ph.D.
18:15 – 19:00 Inaugural Lecture
  Updates on the clinical diagnosis and treatment of breast cancer 
F. Marques, M.D., Ph.D.
Sunday, OctOber 14th
09:00 – 10:30 Breast theoretical session: 
 1. Updates on core needle biopsy of the breast
  2. Issues in the assessment of axillary sentinel lymph nodes  
Nour Sneige, M.D., Ph.D.
10:30 – 11:15 sysmex conference: 
  How do use tnM in breast cancer when axillary dissection is not perfomed? 
new tools to predict nodal involvement.
 Vicente Peg, M.D.
11:15 – 11:45 COffEE bREAk & SlidE REAdingS
11:45 – 12:45 Breast practical session:  
 Nour Sneige, M.D., Ph.D.
 Clinical satellite Conference*
11:45 – 12:45  Updates on the clinical diagnosis and treatment of salivary gland tumors 
António Moreira da Costa, M.D.
12:45 - 14.00 lunCh
14:00 – 15:30 salivary gland theoretical session: 
 1.  Molecular Advances in salivary Gland Pathology and their Practical 
Application
  2. salivary duct carcinoma - update 
Alena Skálová, M.D., Ph.D.
15:30 – 16:30 COffEE bREAk & SlidE REAdingS
16:30 – 17:30 salivary gland practical session  
 Alena Skálová, M.D., Ph.D.
 Clinical satellite Conference*
16:30 – 17:30  Flow cytometry in the diagnosis of lymphomas 
–  the experience of Centro Hospitalar do Porto 
Margarida Lima, M.D., Ph.D.
MOnday, OctOber 15th
09:00 – 10:30  Lymphoma theoretical session: 
 1. Follicular lymphoma microenvironment
 2. the pathology of aggressive non-Hodgkin’s lymphomas 
 Pedro Farinha, M.D., Ph.D.
710:30 – 11:30 COffEE bREAk & SlidE REAdingS
11:30 – 12:30 Lymphoma practical session 
 Pedro Farinha, M.D., Ph.D.
 Clinical satellite Conference*
11:30 – 12:30  Updates on the clinical and radiological diagnosis of bone and soft tissue tumors 
João Pires, M.D. & Pedro Cardoso, M.D.
12:30 – 14.00 lunCh
14:00 – 15:30 Bone and soft tissues theoretical session:
 Molecular and cytogenetic aspects of soft tissue and bone tumors 
 Eduardo Zambrano, M.D., M.S.
15:30 – 16:30 COffEE bREAk & SlidE REAdingS
16:30 – 17:30 Bone and soft tissues practical session 
   Eduardo Zambrano, M.D., M.S.
tueSday, OctOber 16th
09:00 – 10:30 theoretical session on cutaneous melanocytic lesions
 1. Melanocytic lesions at special sites
  2. Benign melanocytic lesions looking malignant 
Boštjan Luzar, M.D., Ph.D.
10:30 – 11:30 COffEE bREAk & SlidE REAdingS
11:30 – 12:30 Practical session on cutaneous melanocytic lesions 
 Boštjan Luzar, M.D., Ph.D.
 Clinical satellite Conference*
11:30 – 12:30 Updates on pathology of pulmonary hypertension 
 Abílio Reis, M.D.
12:30 – 14.00 lunCh
14:00 – 15:30 theoretical session on pleuropulmonary and mediastinal diseases 
 1. overview of pleural mesothelioma
  2. thymic carcinoma: update of current 
Giovanni Falconieri, M.D.
15:30 – 16:30 COffEE bREAk & SlidE REAdingS
16:30 – 17:30 Practical session on pleuropulmonary and mediastinal diseases 
 Giovanni Falconieri, M.D.
 Clinical satellite Conference*
16:30 – 17:30 Ipilimumab: immunotherapy on the treatment of advanced melanoma 
 Ana Raimundo, M.D.
 Closing lecture 
17:30 – 18:00  the Portuguese Cancer League new strategies against cancer 
 Vítor Veloso, M.D.
 Closing remarks  
 J.R. Vizcaino, M.D.& R.Henrique, M.D., Ph.D.
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CoURse FACULtY
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Charles University, 
Faculty of Medicine, 
Plzen, Czech Republic
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University of Ljubljana, 
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Medical College of Wisconsin, 
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Department of Pathology, 
General University Hospital, 
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nour sneige, M.D., Ph.D. 
MD Anderson Cancer Center, 
Department of Pathology, 
Houston, Texas, USA
Pedro Farinha, M.D., Ph.D.
Centro Hospitalar de Lisboa Central
Serviço de Anatomia Patológica
Lisboa, Portugal
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Servicio de Anatomía Patológica
Hospital Universitario Vall d’Hebron
Barcelona, España
CLInICAL sAteLLIte
ConFeRenCe FACULtY
Abílio Reis, M.D.
Serviço de Medicina
Centro Hospitalar do Porto
Ana Raimundo, M.D.
Serviço de Oncologia Médica
Instituto Português de Oncologia do Porto
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Serviço de Cirurgia Geral
Centro Hospitalar do Porto
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Serviço de Radiologia
Centro Hospitalar do Porto
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Serviço de Hematologia Clínica
Centro Hospitalar do Porto
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Serviço de Ortopedia
Centro Hospitalar do Porto
InAUGURAL LeCtURe
Franklin Marques, M.D., Ph.D.
Serviço de Oncologia 
Centro Hospitalar do Porto
CLosInG LeCtURe 
Vítor Veloso, M.D.
Presidente do Núcleo Regional do Norte da
Liga Portuguesa Contra o Cancro.
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To the departamento de Ensino, formação e investigação (dEfi) (department of Teaching, 
Education and Research) for their unconditional support
To the Course faculty for their knowledge and generosity
To the Participants for their determination and support
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the Course has been made possible through the kind support of
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Serviço de Oncologia, Centro hospitalar do Porto
franklim Marques, M.d., Ph.d. is Senior Consultant of Medical Oncology (1998) and head of the 
Oncology division, department of Medicine, hospital de Santo António, Centro hospitalar do Porto, 
Portugal since 2002. he has been exclusively dedicated to Medical Oncology (1989), became member 
of The European Society for Medical Oncology (ESMO) in 1990 and has received the title of European 
Oncologist by ESMO in 1991.
Professor franklim Marques was invited Associated Professor of Medicine, instituto de Ciências 
biomédicas Abel Salazar (iCbAS), Porto, Portugal from 1986 to 1997 (disciplina de Clínica Médica iii) 
and invited Assistant Professor of iCbAS, responsible for Oncology Area (disciplina de Clínica Médica 
ii) since 1998. he has been mentor in the Master degree thesis of 24 iCbAS medical students.    
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Updates on the clinical diagnosis and treatment of breast 
cancer
Cancers or neoplasms are autonomous growths of tissues that have escaped normal restraints on cell 
proliferation and exhibit varying degrees of fidelity to their precursors. 
based on the glObOCAn 2008 estimates, about 12.7 million cancer and 7.6 million cancer deaths are 
estimated to have occurred in 2008; of these, 56% of cases and 64% of deaths occurred in the economically 
developing word.
global burden of cancer continues to increase largely because of the aging and growth of the population 
alongside an increasing adoption of cancer-causing behaviors.
More than 50% of cancers could be prevented implementing what is already known, mostly through lifestyle 
modifications and higher-cost interventions.
Worldwide, breast cancer is the most frequently diagnosed life-threatening cancer in women and the 
leading cause of cancer death among women. in 2008, the estimated numbers of breast cancer cases and 
deaths in Europe were 425147 and 128737 respectively, accounting for 28.2% the total new cancer cases 
and 17% of the total cancer deaths.
increased public awareness and improved screening have led to earlier diagnosis, at stages amenable to 
complete surgical resection and curative therapies. Consequently, survival rates for breast cancer have 
improved significantly.
The general approach to evaluation of breast cancer has become formalized as triple assessment: clinical 
history and examination, imaging (usually mammography and/or ultrasonography), and needle biopsy. 
Surgery is considered primary treatment for early breast cancer. Some patients with early-stage breast 
cancer are cured with surgery alone. because breast cancer has the tendency to early metastasize, 
adjuvant treatment (loco regional radiotherapy, hormone therapy, chemotherapy and directed therapy) 
have indication in the great majority to treat micrometastatic disease, or breast cancer cells that have 
escaped the breast but which have not yet had an established identifiable metastasis. updates on axillary 
lymph node dissection, sentinel lymph node dissection strategies and adjuvant therapy are presented and 
discussed.
The pathogenesis of breast cancer is still poorly understood, but epidemiologic, molecular and genetic 
studies are outlining complex risk factors. breast cancers exhibit diversity in histopathology, molecular 
features, and overall patient outcomes. Tailored treatment recommendations are summarized.
notes
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Nour Sneige
Md Anderson Cancer Center, department of Pathology, 
houston, Texas, uSA
nour  Sneige, M.d., Ph.d. is Professor at the department of Pathology, division of Pathology/lab 
Medicine, The university of Texas Md Anderson Cancer Center, houston, Texas since 1993. She 
graduated in Science (1967) and Medicine (1972) in damascus university, damascus, Syria and 
has received extensive postgraduation training in the united States. following the pioneer work of 
cytopathogists at karolinska hospital, and under the directorship of her former chairman dr. John 
batsakis, lead the establishment of the fine needle Aspiration Clinic at Md Anderson Cancer Center in 
1985. This clinic was the first of its kind in the medical center and was also one of a handful of clinics 
operated by cytopathologists in the nation. This service along with the fnA service of deep-seated 
lesions, which is performed by the radiologists and whose specimens are immediately assessed by the 
cytopathologists, grew rapidly and has replaced open surgical biopsy in many cases. As the director of 
Cytopathology for the past 10 years, she was instrumental in creating and maintaining the Section of 
Cytopathology as a premier center of excellence for the practice of “the state of the art” cytopathology. 
As early as 1989, she introduced the breast Pathology Subspecialty Service, standardizing specimen 
evaluation, pathology reporting and assessment of prognostic and predictive markers. She established 
the breast Tissue bank and was the pathologist in charge for that specialty for 10 years. She also initiated 
in-house testing of breast cancer cases for hER-2 gene amplification by fiSh technique, which proved 
to be the most reliable technique for targeted monoclonal antibodies therapy. in addition to serving 
the MdACC patients, this lab has been sought out by outside investigators for their research as well 
as validation studies. her contribution to clinical research is demonstrated throughout the numerous 
publications in high quality peer reviewed journals. her commitment to five editorial advisory boards 
and presentations of several invited lectures at the national and international levels also attest her 
accomplishment and reputation in the field of breast pathology and cytopathology. She is frequently 
sought after as a consultant on difficult breast cases, inside and outside the institution.
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Vicente Peg
Servicio de Anatomía Patológica,  
hospital universitario Vall d’herbron, barcelona, España
Vicente Peg Cámara graduated in Medicine and Surgery in the university of Zaragoza and received 
the Pathology Residency Training at the university hospital Vall d’hebron, barcelona and also did and 
observational stage at the Massachusetts general hospital in boston (uSA). Then he returned to the 
department of Pathology, h.u. Vall d’hebron joining the Staff Attendings and becoming the group 
leader of breast Pathology. Since then he has led several research projects related to breast cancer 
and has participated in several national and international clinical trials. he is the author of numerous 
publications and usual participant and speaker at scientific meetings. his main research focuses on 
cell signaling pathways in breast cancer and its relation to neoadjuvant chemotherapy treatments as 
well as hypoxia states and in the study of breast sentinel lymph node. he is an Associate Professor at 
the universitat Autonoma de barcelona since 2012.
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How do use TNM in breast cancer when axillary dissection 
is not perfomed? New tools to predict nodal involvement. 
Since its first description and despite the passage of years, the study of the sentinel lymph node (Sln) has 
always had the problems of evaluation subjectivity and difficult analysis standardization. The advent of 
molecular techniques such as the One Step nucleic Acid Amplification (OSnA) from Sysmex (kobe, Japan) 
has managed to make it an automated, standardized and reproducible technique.
however, even with the efforts to achieve a Sln unified analysis, many studies have shown that between 
40% and 60% of cases (analyzed by conventional techniques), the Sln is the only affected node, being the 
remaining axillary lymph node dissection (Alnd) unnecessary. furthermore, the results of the recently 
published study Z0011 from A.E. giuliano group have shown that even having 1 or 2 positive Slns, the 
Alnd can be avoided in a particular subgroup of patients.
One of the direct consequences of the Alnd removal is the preclusion to make a correct axillary lymph 
node staging (pn). in turn, there remains a non-negligible group of patients who meet the inclusion criteria 
for the A.E. giuliano study which are directly pushed into axillary surgery, regardless of the size of the 
metastases in the Sln. finally, we must not forget that this study includes primarily a subgroup of patients 
with good prognosis. for these and several other reasons, nomograms that predict the axillary status taking 
into consideration a series of clinicopathological parameters are still being used today for therapeutic 
decisions, being the most well-known the one proposed by the Memorial Sloan-kettering Cancer Center, 
new York.
The OSnA method provides a new element in the Sln study, the tumor load, defined as the number of 
copies/μl of Ck19 mRnA. little is known of this value so far, so we decided to study its possible predictive 
value for axillary status. for this we have defined the concept of Total Tumor burden (Total Tumor load - 
TTl) as the sum of the tumor burden of all affected Slns of 108 patients (obtained from h.u. Vall d’hebron 
de barcelona and from h. Clínico de Salamanca) and elaborated a ROC curve. in the univariate analysis, the 
TTl was the best predictor of axillary involvement (p = 0.003), only influenced by the hormonal status. in 
multivariate analysis, the correlation persisted. The area under the curve was 0.715.
These data demonstrate that the TTl is a new available tool for the management of patients with breast 
cancer. Compared to other existing current nomograms, it is based on an objective, automated, reproducible 
and standardized variable that, in addition, can be obtained intraoperatively. Prospective studies are being 
carried out to know the real clinical significance of this variable. however, as of today, it seems useful as 
a predictor of axillary involvement and can help the individualized clinical management of certain patients 
with early breast cancer. 
notes
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António Moreira da Costa
Centro hospitalar do Porto, Serviço de Cirurgia geral
graduated from the faculty of Medicine, university of Porto, 1981
Resident of general Surgery in hospital de Santo Antonio, 1985-91
Joined the Attending Staff of the department of Surgery, hospital Santo Antonio, 1992
became Consultant Surgeon in 1999
Appointed to the head and neck, breast and Endocrine unit in 2008 (resigned in 2009 due to health 
condition)
Currently Assistant head of the department of Surgery, responsible for Post graduate Education and 
Pre graduate teaching
One hundred presentations in national and international Congresses and Symposia related to the 
head and neck and Endocrine Surgery
Ten scientific articles published in Portuguese medical journals related to the thyroid, parathyroid and 
head and neck Surgery
Member of the Portuguese Surgical Society and its Endocrine Section
Member of the international Surgical Society
Member of the Royal College of Surgeons of England
56
Updates in diagnosis and treatment of salivary gland 
tumours
I – Anatomy of the salivary glands
Salivary glands are divided into major and minor.
The major salivary glands are paired and comprise the parotid, submandibular and sublingual glands. 
The parotid glands are located in front of the ear, lying over the ascending ramus of the mandible, with an 
elongated shape and present a variable extension caudally, which is termed the tail of the parotid gland. 
They have a variable extension forward, toward the mouth, over the buccinator muscle and are drained by 
a short duct, Stensen’s duct, which opens in the jugal mucosa opposite the second pre-molar tooth of the 
maxilla.
The parotid is not a lobulated gland, contrary to common description; rather, it is compact, with a superficial 
and a deep portion, and is traversed by the main and secondary branches of the facial nerve. This nerve is 
the most important anatomic relation of the parotid.
Other important structures that are intimately related to the parotid gland, and may have to be taken into 
consideration when operating on it are the external carotid artery and the retro-mandibular vein.
There is an important anatomical marker, which is very helpful in locating the main trunk of the facial 
nerve: it is called the pointer; the pointer is best assed by pressing the tip of the index finger onto the space 
between the mastoid process and the cartilaginous portion of the external auditory canal: at the tip of the 
finger the styloid process will be felt, and behind it will appear the facial nerve.
The submandibular gland is also paired. it is located on the anterior half of the submandibular triangle, 
bounded above by the horizontal ramus of the mandible, anteriorly by the midline and posteriorly by the 
anterior belly of the digastrics muscle.
it is elliptical and is drained by Wharton’s duct, a short structure that opens at the floor of the mouth, near 
the fraenulum of the tongue. its most important anatomic relations are the facial vessels, artery and vein, 
which traverse the gland, and the hypoglossal, lingual and marginal mandibular branch of the facial nerve.
The sublingual gland is a paired structure, located on either side of the lingual fraenulum, rod-like, and 
that has no single collecting duct, rather opening into the floor of the mouth by means of a variable number 
of orifices.
in addition, there are countless numbers of minor salivary glands, present in the mucosa of the mouth, 
labial, gingival, lingual, jugal and palatal. They drain directly into the mouth.
II – Phisiology of the salivary glands
The main function of the Salivary glands is the production of saliva.
Saliva is the watery fluid that keeps the mouth moist and performs a certain number of digestive and 
bactericidal functions.
Saliva is composed of water, variable amounts of mucous, sodium bicarbonate, and enzymes.
The larger the gland, the greatest the content in water and bicarbonate of its saliva, and the smaller the 
gland, the larger its production of mucus.
Saliva contains variable amounts of salivary amylase, which starts the break-down process of the simplest 
sugars contained in the diet. it also contains lysozime, similar to that contained in tears, which helps 
in controlling the bacterial flora of the mouth. nonetheless, a human bite is the most infectious of all 
carnivore bites.
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III – Benign salivary gland neoplasms
The salivary glands can harbour a variable number of benign neoplastic proliferations.
The larger the gland, the likelier will a neoplasm be.
The most common benign tumour that presents in the salivary glands is the Pleomorfic Adenoma.
Other benign neoplasms include Whatin’s Tumour, Oncocytic Adenoma, Mio-epithelial Adenoma, 
various cysts and other less common types.
Clinical presentation is dominated by the appearance of a lump or mass, which is characteristically 
painless, firm or soft in consistency, that exhibits a slow tendency to grow and that does not involve 
the facial nerve by direct extension.
diagnostic work-up is based on imaging studies (ultrasound or more seldom, CT scan or MRi) and 
fnAb. Pre operative diagnosis can be established with a very high degree of accuracy.
The treatment of choice, and almost the universal mode of treatment, is surgical excision of the 
affected gland.
Surgery is variable, according to the affected gland, but, generally, involves the complete excision 
of the gland, with special attention to clear surgical margins, owing to the very high rate of local 
recurrence if resection is marginal, tangential or if diseased gland is intersected.
if this occurs, consideration should be given to complementary treatment with Radiotherapy.
Associated surgical morbidity is rare, with the main concern lying on nervous injuries, inadvertently 
incurred intraoperatively.
Prognosis is excellent with cure rates approaching 100%.
IV – Salivary gland cancer
Salivary gland cancer is a very rare occurrence. it comprises only 0.5% of all malignancies and less 
than 5% of all head and neck cancers.
As stated before, the larger the gland, the less probable will any tumour arising in it be malignant; 
conversely, most tumours of the minor and medium sized salivary glands will be malignant.
These forms of cancer are characterized by a very diverse clinical course, which is dependent mainly 
on hystopathological type, stage at diagnosis and initial effectiveness of treatment.
The most common histological types are. Mucoepidermoid Carcinoma, Squamous Cell Carcinoma, 
Acinic Cell Carcinoma, Adenoid Cystic Carcinoma and Adenocarcinoma nOS.
They generally present as painless mass or lump, which exhibits a variable growth pattern. Signs of 
nervous involvement, such as facial or hypoglossal or mandibular marginal nerve palsy are indicative 
of an advanced stage. So is the presence of cervical lymphadenopathy.
diagnostic work up is basically the same as for benign tumours:  imaging studies (ultrasound, 
Quantitative dynamic contrast-enhanced MRi, diffusion- weighed MRi, CT scan, PET scan) and the 
use of fnAb. A relatively new diagnostic approach consists in the use of uS-guided Core biopsy. This 
last modality seems to be superior in diagnostic accuracy to fnAb, but carries a higher risk of facial 
nerve injury.
The mainstay of treatment for salivary gland Cancer is Surgery, with performance of intra-operative 
frozen section examination whenever there is no certainty of pre- operative diagnosis.
Surgical principles are the same also, only more stringent: radical gland excision, absolute clear 
margins. if there is pre operative confirmation of nerve involvement, nerves must be deliberately 
sacrificed.
in the cases of suspected or confirmed pre-operative lymph node metastases, a neck dissection is 
mandatory: its variable forms – Classical Radical, Modified Radical, and functional – will be determined 
by the extension of lymph node involvement, by tumour grade and by clinical staging of the neoplasm.
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There are several available options for adjuvant therapy: Radiotherapy, Chemotherapy with conventional 
drugs and the newest available drugs such as Tk, EgfR and hER 2 inhibitors. All these options offer very 
limited scope for success, and the best chance for cure lies in a properly performed radical operation.
Surgical morbidity can be very distressing and disabling, especially where nerve lesions are concerned. This 
is most acute in those instances of facial nerve injury, be it accidental or deliberate.
There are several forms of minimizing accidental injury, mainly by the use of intra-operative nerve 
monitoring with neuro stimulators.
if the facial nerve is sacrificed, either intentionally or inadvertently, there are several plastic surgery 
techniques, using nerve grafts, obtained from a variety of peripheral sensory nerves, such as the great 
auricular or sural nerves, muscle transfer flaps, such as the sternocleidomastoid flap, tarsorraphy, and so 
on.
for the treatment of frey’s Syndrome, or gustative sweating, which is owed to anomalous nerve regeneration, 
following the rising of facial skin flaps in the performance of parotidectomy, the most common approach 
use nowadays is botox injection, subcutaneously, in the affected area.
Prognosis is variable, and depends on histological type of cancer, its grade, pathological staging and 
completeness and effectiveness of therapy. five year survival rates may vary between 75-100% for low 
grade acinic and polymorphous adenocarcinomas and 15-20% for undifferentiated, salivary duct and ex-
pleomorfic carcinomas.
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Alena skálová
Charles university, faculty of Medicine,  
Plzen, Czech Republic
Alena Skálová, Ph.d., M.d., is Professor of Pathology at Medical faculty in Plzen, Charles university 
Prague, Czech Republic. She graduated in Medicine in 1979, received her board Certificates in 
Pathology 1st and 2nd degree in 1982 and 1989 respectively, presented her Ph.d. thesis in 1991, 
entitled “The role of myoepithelial cells in secretion and deposition of extracellular matrix in salivary 
gland tumors”, was Associate Professor of Pathology at the Medical faculty of Charles university in 
Plzen (thesis entitled “Cell proliferation in salivary glands and in tumors of salivary gland origin) and 
Professor of Pathology since 2001. 
She received Scholarship at the department of Pathology of university of helsinki 2 times (grants 
awarded by finnish Ministry of Education (1991) and Yamagiwa-Yoshida Memorial international 
Cancer Study grant - awarded by international union Againts Cancer uiCC in geneva (1993)) and 
again a Study grant from uiCC (international union against Cancer) (1996). her contribution to 
scientific research and medical literature is demonstrated throughout the numerous publications in 
high quality peer reviewed journals and as an author in several reference books including the W.h.O. 
Classification of Tumours. She has received numerous scientific awards and was committed to several 
invited lectures at the national and international levels, attesting her accomplishment and reputation 
in the field of Salivary gland Pathology.
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Molecular Advances in Salivary Gland Pathology and their 
Practical Application
The review describes the new findings in salivary gland pathology. newly recognized entities include 
sclerosing polycystic adenosis (SPA) initially believed to be reactive/inflammatory lesion similar to fibrocystic 
disease of breast. Recent molecular study using the huMARA (human androgen receptor assay) for clonality 
analysis demonstrated that SPA is clonal, and thus most likely neoplastic process (1).
Three salivary gland tumors have newly described interesting molecular profiles that warrant discussion: 
mucoepidermoid carcinoma, adenoid cystic carcinoma, and a recently described tumor, mammary analogue 
secretory carcinoma (MASC).  
Mucoepidermoid carcinoma (MEC) is a common salivary gland tumor that occurs in both major and minor 
salivary glands. The tumor has variable clinical course with some tumors having excellent behaviour while 
the others are characterized by rapid poor clinical outcome. Conventional clinicopathological parameters 
such as stage and grade are among the most significant prognosticators (2,3). however, histological grade 
is not entirely predictive of biological behaviour in all patients, particularly in low and intermediate grades. 
Therefore, a more objective consistent prognosticator is desirable for stratifying patients with MEC into 
appropriate treatment groups. A specific chromosomal translocation has been recently recognized in MEC, 
t(11;19)(q21;p13), which fuses MECT1 (mucoepidermoid carcinoma translocated-1) at 19p13 with MAMl2 
(mastermind-like gene family) at 11q21. The MECT1/MAMl2 fusion transcript, present in more than half 
of MECs, is associated with lower histological grades and improved survival, suggesting both diagnostic 
and prognostic roles in clinical management (4). Moreover, MEC cases MECT1/MAMl2 fusion positive form 
a favourable tumor subset that seems to be distinct from fusion-negative cases. When positive for the 
fusion, even “high-risk” patients including those with a higher histological grade or an advanced clinical 
stage showed an excellent prognosis (5).
Adenoid cystic carcinoma (AdCC) is a common tumor that occurs in both minor and major salivary glands. 
The tumor often has a relentless clinical course that includes late recurrences and distant metastatic 
disease. Recently, the translocation between chromosomes 6 and 9 was described both in AdCC of breast 
and salivary glands. This translocation fuses the MYb gene and the nfib gene, which lead to characteristic 
chimeric transcript (6).  The MYb/nfib fusion transcript, present in at least one third of AdCCs, has emerged 
as  a potential therapeutic target (7).
Mammary analogue secretory carcinoma (MASC) of salivary glands was recently described as a new entity 
characterized histologically by resemblance to secretory breast cancer (8). it was demonstrated that MASCs 
harbour a recurrent balanced chromosomal translocation t(12;15)(p13;q25), which leads to a fusion gene 
between the ETV6 gene from chromosome 12 and the nTRk3 gene from chromosome 15, exactly as in 
secretory breast cancer (8). 
Another interesting new entity is cribriform adenocarcinoma of minor salivary gland origin affecting 
principally the tongue (CAT). This is an infiltrative tumor that occurs almost exclusively in the base of the 
tongue (9). despite overlapping histological and immunohistochemical features with polymorphous low 
grade adenocarcinoma of minor salivary glands, CAT represents genuine entity with high frequency of 
cervical lymph node metastasis at presentation (9).
finally, „dedifferentiation“ or high grade transformation of salivary carcinomas is discussed. The concept 
of „dedifferentiation“ in salivary gland tumor pathology means identification of clonal evolution of poorly 
differentiated  (high grade) elements arising in low-grade carcinoma. This is in contrast with malignant 
transformation of originally benign tumors, such as carcinoma ex pleomorphic adenoma. in recent years, 
a variety of low grade salivary carcinomas, such as epithelial-myoepithelial carcinoma (10), adenoid cystic 
carcinoma (11), and acinic cell carcinoma (12), have been documented to progress to high grade carcinoma 
with consequent aggressive clinical behavior.
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Salivary duct carcinoma: an update
Salivary duct carcinomas (SdC) are rare tumors with a very poor clinical outcome. SdC is defined in 
the 2005 World health Organization (WhO) classification as „an aggressive adenocarcinoma which 
resembles high grade breast carcinoma“ (1). These tumors comprise epithelial structures in solid, 
papillary-cystic, tubular, trabecular, and cribriform patterns and often display prominent nuclear and 
cellular polymorphism. Central comedo-like necrosis and perineural invasive growth are common 
findings. Most cases of SdC arise de novo, although some develop as the malignant component of 
carcinoma ex pleomorphic adenoma. The diagnostic clue in most cases of SdC is an intraductal in 
situ component comprising mostly solid and cribriform patterns similar to ductal carcinoma in situ 
(dCiS) of the breast.
Several morphological variants of SdC have been recently described. Mucin-rich variant is composed 
of areas of mucinous/colloid carcinoma in which clusters of carcinoma cells float in mucin pools (2). 
invasive micropapillary variant of SdC is characterized by tumor cell clusters without fibrovascular 
cores, surrounded by a clear space, morphologically similar to micropapillary breast cancer. This 
variant appears to be associated with very aggressive clinical behaviour (3). Sarcomatoid variant of 
SdC comprises, in addition to conventional SdC, also admixed sarcomatoid component, within which 
there are anaplastic spindly and bizarre multinucleated giant cells (4). Although intraductal in situ SdC 
is not recognized as an entity by the 2005 WhO classification (1), occasional cases have been described 
(5) characterized by a pure intraductal proliferation of tumor cells, similar to intraductal carcinoma of 
the breast. in recent study, three cases of high grade in situ SdC were demonstrated, characterized 
by intraductal proliferation of neoplastic high grade ductal cells with co-expression of Ck7, androgen 
receptors and hER-2/neu surrounded by complete myoepithelial cell layer  (6). 
Salivary duct carcinoma (SdC) and invasive ductal carcinoma (idC) of the breast have well documented 
histomorphological similarities. Microarray studies have demonstrated that mammary idCs can be 
subclassified into biologically and clinically distinctive molecular subgroups: luminal, hER-2 neu, 
basal-like, and normal breast-like cancers (7). Subsequently, a panel of immunohistochemical markers 
which can be used as a surrogate of gene expression analysis to classify breast carcinomas into 
molecular subgroups was described (8). The aim of our study was to apply an immunohistochemical 
panel previously validated for breast cancer to determine whether SdCs could likewise be classified 
into analogous molecular groups.
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We used a modified version of the immunohistochemical panel for the classification of breast cancers into 
the molecular subgroups proposed by nielsen et al. (8). Sixty four cases of salivary duct carcinomas (including 
SdC ex pleomorphic adenoma) were retrieved from the files and reviewed. All of them fulfilled the criteria for 
SdC according to the WhO classification (1). The tumors were stained with antibodies for estrogen receptor 
(ER), progesterone receptor (PR), androgen receptor (AR), hER-2/neu, epidermal growth factor receptor 
(EgfR), cytokeratin 5, and cytokeratin 5/6. hER-2/neu status was assessed by immunohistochemistry and 
fluorescence in situ hybridisation (fiSh). Cases were classified using criteria described previously (9). hER-2/
neu phenotype was determined if the tumor cells expressed hER-2/neu protein (score 3+) and harboured 
the hER-2/neu gene amplification, regardless of the expression of other markers. Tumors lacking hER-2/
neu expression which expressed ER, PR or AR, were considered of luminal phenotype, again regardless of 
the expression of other markers. Cases negative for hER-2/neu, ER, PR or AR which expressed either EgfR 
or Ck 5/6 were considered of basal-like phenotype. Carcinomas which were negative for all markers were 
considered of indeterminate phenotype (9).
The majority of SdCs in our series represent the luminal subtype (23 cases, 38 percent of the invasive 
SdC). The second most prevalent group was hER-2/neu subtype (20 cases, 33 percent of the invasive SdC), 
whereas 12 cases fulfilled the criteria of the basal-like phenotype (19 percent of the invasive SdC). nine 
cases of SdC (10 percent) were considered indeterminate phenotype. 
incidence of hER-2/neu positive subtype of SdC is consistent with other large recent studies (10, 11) but 
notably lower than in our previous report based only on 11 cases of SdC (12). The difference can be attributed 
to selection of cases using hER-2/neu immunostaining as a hallmark of SdC in our earlier study (12). in our 
new series, the cases were considered salivary duct carcinomas if they resembled a high grade ductal 
carcinoma of the breast, lacked any features suggestive of other specific types of salivary malignancy, and 
displayed expression of cytokeratin Ck 7.
in conclusion, our results demonstrate that salivary duct carcinomas can be classified into molecular 
subgroups approximately equivalent to those in the breast. The study also shows that a considerable 
subset of SdC represents the hER-2/neu phenotype, and therefore selected patients with SdC may benefit 
from therapeutic use of trastuzumab (herceptin) similar to the treatment in breast cancer.
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CASE 1.  A 50-year-old woman presented with painless swelling in buccal 
mucosa. The tumor had been present for approximately one year 
before surgery and it was gradually growing. The tumor was well 
circumscribed, and it measured 1 cm in diameter. No lymph node 
metastases were present. The patient is well alive with no recurrent 
disease within 6 year follow-up.
 
Diagnosis: Mammary analogue secretory carcinoma (MASC).
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CASE 2.  A slowly growing tumor of parotid gland in 17-y old girl measured 
2.7x1.7x1.2 cm. Superficial parotidectomy was performed. The 
patient is well 5 years after surgery with no evidence of disease.
Diagnosis: Well differentiated acinic cell carcinoma with lymphoid stroma 
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CASE 3.  57-y-old man presented with long lasting painless swelling in right 
parotid gland. The CT scan showed a well circumscribed tumor 3 cm 
in diameter. The tumor was surgically removed by enucleation. No 
recurrence was observed in 4 year follow-up period.
Diagnosis: Sclerosing polycystic adenosis
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CASE 4.  72-year old woman presented with cervical lymph node metastasis. 
The specimen was sent in consultation with preliminary diagnosis 
of primary pathologist was a lymph node metastasis of thyroid 
gland papillary carcinoma.  In our consultation, we have suggested 
to examine the oral cavity, in particular the tongue of the patient. 
Two months later, the patient was operated, and surgical specimen 
disclosed a well circumscribed tumor of the radix of the tongue. The 
slides come from the tongue specimen.
Diagnosis: Cribriform adenocarcinoma of the tongue type (CATS)
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CASE 5.  A 53-year-old woman presented with a tumor of soft palate of 6 
months duration
Diagnosis: Polymorphous low grade adenocacinoma (PlgA)
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CASE 6.  63-year old man presented with rapidly growing tumor in the parotid 
gland. Grossly the tumor measured 6x5x2 cm. One cervical lymph node 
was involved by metastasis at the same time. The patient died two year 
later with multiple cervical lymph node and distant lung metastases.
Diagnosis: Salivary duct carcinoma 
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CASE 7.  26-year old woman presented with slowly growing tumor in the 
parotid gland. Grossly, the tumor measured 1.5 cm in diameter. No 
recurrence is noted 10 years after surgery.
Diagnosis: Pleomorphic adenoma with unusual features
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CASE 8.  70-year old man presented with non-healing ulceration in molar region 
after extraction of the tooth 4 years earlier.
Diagnosis: hyalinizing clear cell carcinoma of minor gland
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CASE 9.  A 76-year old woman presented with a rapidly growing tumor of parotid 
gland. Radical parotidectomy and cervical lymph node dissection of left 
side was performed, and followed by radiotherapy. The patient died 
after two years because of cancer dissemination (metastases in multiple 
lymph nodes and lungs). No autopsy performed.
Diagnosis: high grade transformation of acinic cell carcinoma
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Flow cytometry in the diagnosis of the mature lymphoid 
neoplasms: experience of the centro hospitalar do porto.
Over the last years, flow cytometry has gained an increasing importance in the diagnosis and 
characterization of the haematological malignancies. When combined with cytological and histological 
studies, immunophenotyping is of a great help to distinguish reactive processes from neoplastic 
diseases, as well as to accurately diagnose and categorize most of the mature lymphoid neoplasms. 
besides its general application in the study of peripheral blood and bone marrow samples, its role on 
the investigation of fine-needle aspirates, serous effusions, cerebrospinal fluid and other body fluids 
has became more and more relevant as an important complement to the cytological diagnosis in these 
problematic biological samples. At the same time, cell suspensions obtained from core and surgical 
biopsies are used with increasing frequency for immunophenotyping, complementing the information 
obtained in the histological and immunohistochemistry studies of the different organs and tissues. 
in addition, cytogenetic and molecular tests are helpful in identifying specific chromosomal and gene 
defects associated with particular disease entities or with prognostic significance.
flow cytometry allows for an accurate identification of different b-cell reactive patterns observed in lymph 
nodes, such as follicular hyperplasia, whenever a typical reactive germinal centre b-cell immunophenotype 
is found; parafollicular hyperplasia can also be suspected based on the preferential expansion of otherwise 
normal activated Cd4+ T cells. in addition, evidence for a polyclonal b cell expansion, with or without 
lymphoplasmacytic differentiation, and/or characteristic T- and/or nk-cell activation related patterns are 
observed in the peripheral blood from patients with reactive lymphocytosis. 
Most mature b- and T- and nk-cell neoplasms that are recognized as independent disease categories in 
the World health Organization (WhO) classification can be easily diagnosed by flow cytometry because of 
their unique phenotypic features. This applies to b-cell chronic lymphocytic leukaemia/small lymphocytic 
lymphoma, mantle cell lymphoma, follicular lymphoma and hairy cell leukaemia, among others. diffuse 
large b cell lymphomas are also identify by simultaneously analysing the immunophenotype and the light 
scatter properties of the neoplastic b-cells; however, this particular group of mature b-cell neoplasms is 
very heterogeneous phenotypically, probably because they comprise several distinct pathological entities. 
The diagnosis of some disease entities by flow cytometry, such as the marginal zone b cell lymphoma is 
still of exclusion and the identification of other specific disease types, including b-cell prolymphocytic 
leukaemia and lymphoplasmacytic lymphoma, still relies on conventional morphological studies. for 
instance, the diagnosis of the former depends on the presence of prolymphocytes in the blood, whereas 
the latter is diagnosed mainly based on the morphological evidence of lymphoplasmacytic differentiation. 
in that concerning plasma cell disorders, flow cytometry proved to be an important tool to identify and 
quantify, as well as to distinguish normal from monoclonal / phenotypically aberrant plasma cells. using 
flow cytometry, we are able to discriminate monoclonal gammapathies of undetermined significance 
from multiple myeloma cases, to identify groups with different prognosis among patients with plasma 
cell myeloma, as well as to monitoring the response to therapy, at levels of minimal residual disease. 
Other plasma cell neoplasms, such as plasma cell leukaemia and plasmacytoma, are also easily diagnosed 
by flow cytometry. 
in concerning mature T- and nk-cell neoplasms, flow cytometry allows for an accurate distinction between 
reactive (activated) and neoplastic T- and nk-cells in most occasions, based on the identification of 
activation-related or aberrant phenotypic profiles; in addition, the identification of clonally expanded 
T-cell populations can be facilitated by studying the repertoires of families of the T-cell receptor chains 
variable regions. T-cell prolymphocytic leukaemia, Sezary syndrome and T-cell large granular lymphocytic 
leukaemia are easily diagnosed by flow cytometry, especially if conjugated with clinical and morphological 
features. The same occurs for specific peripheral T-cell and nk-cell lymphoma subtypes with unique 
immunophenotyping profiles (e.g. hTlV-i associated T-cell leukaemia / lymphoma, angioimmunoblastic 
T cell lymphoma, and hepatosplenic T cell lymphoma, extranodal nk cell lymphoma, nasal type). in 
contrast, routine flow cytometry usually fails to diagnose hodgkin lymphoma, as well as particular non-
hodgkin lymphoma subtypes, such as anaplastic large cell lymphoma, for which specific staining and/
or acquisition flow cytometry protocols are requested in order to establish the diagnosis. nevertheless, 
routine flow cytometry is useful to characterize the reactive lymphocytic infiltrate, which often has a very 
typical composition.
herein we discuss the most relevant aspects concerning the use of flow cytometry in a clinic haematology 
laboratory, focusing on the potentials, advantages, limitations and pitfalls of this technique for the 
diagnosis, classification and monitoring of the tumours of the lymphoid tissues. Moreover, we present 
the experience of the laboratory of Cytometry of the Centro hospitalar do Porto in this area and describe 
the general procedures used in this lab for sample collection, processing and cell staining. finally, we 
summarize the main phenotypic features that characterize the mature lymphoid neoplasms, as defined 
by the 2008 WhO classification schema.
71
Pedro Farinha
Centro hospitalar de lisboa Central,  
Serviço de Anatomia Patológica, lisboa, Portugal
Pedro farinha, M.d., Ph.d. is Staff Attending of the Anatomic Pathology division, Centro hospitalar de 
lisboa Central (ChlC), lisboa, Portugal and Assistant Professor at faculdade de Ciências Médicas de 
lisboa, Portugal. 
he received is Anatomic Pathology Residency Training at the Portuguese institute of Oncology, lisbon, 
Portugal (1998-2003), with Residency Rotation (3 month) in hematopathology at the british Columbia 
Cancer Agency (bCCA), Vancouver, bC, Canada (2001). he did fellowship at Molecular Pathology in 
Oncology (Canadian institute of health Resources - ChiR) at bCCA, Vancouver, bC, Canada (2004-
2006) and fellowship at Clinical hematopathology at bCCA (2006-2007). he has received several 
research or equivalent grants as principal or co-investigator. 
Professor farinha was engaged in Pathology teaching since 1998, became Assistant Professor in 2002 
and since 2010 is co-organizing/teaching the module of Translational Research theoretical course 
and practical training.
he has been instructing residents of Anatomic Pathology since 2007, teaching in hematopathology 
rotations (3months) to both Anatomic Pathology and hematology residents. 
Professor farinha has made more than 60 presentations (more than 30 oral) in international scientific 
Meetings with referees, such as uSCAP, ASh and EAhP annual meetings as well as iCMl, keystone 
Meetings and iwnhl. he was received seven awards. he also did a significant contribution to the medical 
literature with 31 published scientific articles. he is Journal Reviewer at several Medical Journals. he 
was oral Session Moderator & Session Reviewer at the 49th American Society of hematology - Annual 
Meeting in Atlanta 2007 and is Co-organizer of the Annual Meeting of the European Association of 
haematopathology / Society of hematopathology taking place in lisbon, October 2012. 
72
1. Follicular Lymphoma Microenvironment
until recently cancer biology has been focused on the study of the genetic alterations harboured by 
neoplastic cells that distinguished these cells from their normal counterparts.  More recently, the concept 
of cancer ecosystem characterized by co-evolution of tumour clones vs. non-tumoral immune cells through 
complex, diverse and dynamic states with multiple variables, resulted in a growing appreciation of the 
contribution of the tumor microenvironment to the pathogenesis of tumours. in follicular lymphoma, the 
role of microenvironment has gained significant momentum with the evidence of an important clinical 
impact in cancer patients. Moreover, therapy regimens that target tumour microenvironment have shown 
significant and promising results thus being recently approved by fdA. The tumoral microenvironment 
encompasses the accessory and immune-related cells in the immediate vicinity of the tumour cells that 
engage in crosstalk and cell-to-cell contact with the neoplastic cells, typically providing a nurturing milieu 
by providing nutrients, new blood vessel formation and fostering immune privilege. The microenvironment 
may fluctuate between anatomic sites in a given b cell clonal proliferations, probably early in development 
of lymphoma with some sites seemingly creating a niche that promotes acquired drug resistance and 
cancer stem cell maintenance. understanding the role of the microenvironment in lymphoid malignancies 
has also fostered renewed interest in the development of biological agents that act by disrupting the 
growth-promoting interactions or crosstalk between neoplastic and non-neoplastic cells, resulting in a 
potential paradigm shift in therapeutic strategies away from standard chemotherapy alone.  
 
2. The Pathology of Aggressive Non-Hodgkin 
Lymphomas
Aggressive non-hodgkin lymphomas comprise a large group of distinct lymphoid neoplasms, accounting 
for the majority of lymphomas we encounter in daily practice. The list of diseases included under this 
rubric have expanded  recently due to the new genome molecular profiling studies. distinguishing between 
these nhls is frequently highly relevant for the patient, as both treatment and prognosis may be decisively 
affected. importantly, there are new subtypes of lymphomas that are indistinguishable under the microscope 
but originate from lymphocytes that differ in development stage and that use distinct oncogenic programs. 
different lymphoma subtypes will be discussed with emphasis on how to use ancillary techniques essential 
for a correct diagnosis. 
notes
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CASE 1.  60 year-old man with night sweats and a right neck lymphadenopathy. 
Lymph node excisional biopsy.
Diagnosis: Composite lymphoma: diffuse large b cell lymphoma with low & high grade follicular 
lymphoma with associated follicular lympoma in situ.
References
-  Swerdlow Sh et al. World health Organization Classification of Tumours of haematopoietic and lymphoid Tissues. lyon: iARC 
press; 2008.
CASE 2.  38 year-old female with fatigue and an enlarged left axillary lymph 
node. She moved form Western Africa one years before the diagnosis. 
Lymph node excisional biopsy.
Diagnosis: hhV8-associated multicentric castleman disease.
References
1. Swerdlow Sh et al. World health Organization Classification of Tumours of haematopoietic and lymphoid Tissues. lyon: iARC 
press; 2008. 2. Shao h et al. nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative 
disorder with a low risk of clinical progression. Am J Surg Pathol. 2010 Oct;34(10):1425-35.
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CASE 3.  Incidental right neck lymphadenopathy with 2cm in a 72 year-old 
female. Lymph node excisional biopsy.
  
Diagnosis: Angioimmunoblastic t cell lymphoma.
References
-  Swerdlow Sh et al. World health Organization Classification of Tumours of haematopoietic and lymphoid Tissues. lyon: iARC 
press; 2008.
CASE 4.  82 year-old male with pancytopenia and hepatosplenomegaly. Bone 
marrow biopsy.
     
Diagnosis: intravascular large b cell lymphoma.
References
-  Swerdlow Sh et al. World health Organization Classification of Tumours of haematopoietic and lymphoid Tissues. lyon: iARC 
press; 2008.
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CASE 5.  Weight loss, night sweats and increased LDH in 64 year-old man. 
Enlarged retroperitoneal mass on CT scan. Retroperitoneal mass 
incisional biopsy.
    
Diagnosis: b cell lymphoma, unclassifiable with features intermediate between diffuse large b 
cell lymphoma and burkitt lymphoma.
References
1. Swerdlow Sh et al. World health Organization Classification of Tumours of haematopoietic and lymphoid Tissues. lyon: iARC 
press; 2008. 2. Macpherson n et al. Small noncleaved, non-burkitt’s (burkitt-like) lymphoma: cytogenetics predict outcome and 
reflect clinical presentation. J Clin Oncol 1999;17:1558-1567. 3. Savage kJ et al. MYC gene rearrangements are associated with a 
poor prognosis in diffuse large b-cell lymphoma patients treated with R-ChOP chemotherapy.blood. 2009 Oct 22;114(17):3533-7.
CASE 6.  85 year-old man with a left axillary mass. Incisional biopsy.
   
Diagnosis: EbV positive diffuse large b cell lymphoma of the elderly.
References
-  Swerdlow Sh et al. World health Organization Classification of Tumours of haematopoietic and lymphoid Tissues. lyon: iARC 
press; 2008.
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CASE 7.  Multiple lymphadenopathy in a 95 year-old female. Lymph node 
excisional biopsy.
  
Diagnosis: Agressive systemic mastocytosis - lymphadenopathic systemic mastocytosis with 
eosinophilia.
References
-  Swerdlow Sh et al. World health Organization Classification of Tumours of haematopoietic and lymphoid Tissues. lyon: iARC 
press; 2008.
CASE 8.  62 year-old female with weight loss, fatigue and pancytopenia. Bone 
marrow biopsy. 
  
Diagnosis: T cell / histiocyte-rich large b cell lymphoma, micronodular variant.
References
1. Swerdlow Sh et al. World health Organization Classification of Tumours of haematopoietic and lymphoid Tissues. lyon: iARC 
press; 2008. 2. dogan et al. Micronodular T-cell/histiocyte-rich large b-cell lymphoma of the spleen: histology, immunophenotype, 
and differential diagnosis.  Am J Surg Pathol. 2003 Jul;27(7):903-11.
CASE 9.  5cm jejunal mass in a 52 year-old man. Surgical jejunectomy with 30cm.
  
Diagnosis: Enteropathy-associated T cell lymphoma, Type ii.
References
- Swerdlow Sh et al. World health Organization Classification of Tumours of haematopoietic and lymphoid Tissues. lyon: iARC 
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Updates on the clinical and radiologic diagnosis of bone 
and soft tissue tumours 
The presentation will focus on the role of imaging in musculoskeletal neoplasms, diagnostic procedures 
and treatment strategies, including new techniques. 
A brief overlook will be given of modalities used, information provided, limitations, pitfalls and recent 
advances. Radiologic-pathologic integration in certain problems (e.g. cartilage forming tumours, small 
round cell malignancies, giant cell tumours...) will be stressed. 
Although pathology is regarded as the gold standard, clinic-radiologic information and communication 
between specialties is crucial to reach a diagnostic consensus.
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Molecular and cytogenetic aspects of soft tissue and 
bone tumors
Mesenchymal tumors, as a whole, are rare neoplasms, which frequently require the application of complex 
molecular tests for their diagnosis. As more advanced testing is becoming increasingly available to a 
wider population, general surgical pathologists are in need of understanding basic principles of molecular 
pathology in order to be able to interpret complex text results, which may have direct implications in 
the diagnosis, prognosis and targeted treatment of bone and soft tissue tumors. As molecular pathology 
techniques and the tenets of personalized medicine are becoming widespread and common practice, both 
in the academic and the community settings, general surgical pathologists will increasingly be faced with 
having to interpret highly sophisticated molecular test results.
in this session we will deliver an in-depth review of state of the art molecular principles, and their application 
towards the diagnosis and targeted management of bone and soft tissue neoplasms. We will review basic 
principles in molecular biology of bone and soft tissue tumors, and the practical application of that 
knowledge through the appropriate ordering and interpretation of advanced molecular diagnostic tests. 
Attendants will also benefit from reviewing state of the art information related to personalized treatment 
and molecular targeting of specific tumors of bone and soft tissues.      
 
notes
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CASE 1.  62 year-old man presenting with left intra-abdominal “desmoid-
type fibromatosis” recurring as high-grade sarcoma 5 years later.
Diagnosis: dedifferentiated liposarcoma.
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CASE 2.  93 year-old female patient presenting with 15 cm left medial thigh 
deep soft tissue mass.
Diagnosis: Well-differentiated liposarcoma with myxoid changes.
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CASE 3.  14 year-old boy presenting with 1.9 cm “myxofibrosarcoma” involving 
superficial soft tissues of left upper arm.
Diagnosis: Nodular fasciitis.
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CASE 4. 12 year-old girl with 5 x 2.5 cm soft tissue mass of left shoulder.
Diagnosis: Desmoplastic small round cell tumor.
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Problematic melanocytic lesions
Abstract
Most melanocytic lesions in children and adults do not differ histologically from similar types of 
lesions in the adult population. nevertheless, exceptions do exist and a subset of melanocytic naevi 
in children and adolescents display architectural and cytological abnormalities. Such changes are not 
only age-related, they can also be influenced by their occurrence at special sites and under special 
circumstances, and must not be misinterpreted as melanoma.  Essential clinical information thus 
includes the age of the patient and the site of occurrence. 
This review focuses on peculiarities of melanocytic naevi in the first years of life, proliferative nodule 
in congenital naevi, pagetoid Spitz naevus, recurrent naevus, melanocytic naevus with Meyerson’s 
phenomenon, melanocytic naevus with a halo phenomenon, combined melanocytic naevus and deep 
penetrating naevus.
Key words: melanocytic naevi, children, adolescents, congenital melanocytic naevi, proliferation 
nodule, pagetoid Spitz naevus, recurrent melanocytic naevus, Meyerson’s phenomenon, halo naevus, 
combined melanocytic naevus, deep penetrating naevus. 
Congenital nAevi in neonates and young children
Congenital melanocytic naevi are traditionally defined as those present at birth and can be observed 
in 1 to 6% of neonates (1). based on the size of the lesion in adulthood, they are categorized into 
small (less than 1.5 cm), medium-sized (1.5 to 20 cm) and large or giant congenital melanocytic 
naevi (more than 20 cm) (1). lesions larger than 20 cm in size in adulthood correspond roughly to a 
size larger than 9 cm on the scalp and larger than 6 cm on the body of a neonate (2, 3). large or giant 
congenital melanocytic naevi occur in about 1 in 20,000 births (4).
Clinical features
Congenital melanocytic naevi show a tendency for morphological changes over time. The initial 
lesion is usually a flat, evenly pigmented tan to black plaque or patch, which eventually becomes 
elevated and unevenly pigmented (1). Papules, nodules, as well as verrucous or cerebriform changes 
can subsequently develop, which might require histological examination to exclude melanoma. The 
majority of lesions contain increased numbers of terminal hairs. Congenital melanocytic naevi located 
on the scalp show a tendency to lighten and regress over time (1).
Histological features
The majority of melanocytic naevi in neonates and young children display histological features similar 
to those seen in ordinary or congenital melanocytic naevi (5-10). They can be junctional, compound 
or intradermal. The depth of the melanocytic infiltration is generally related to the size of the 
melanocytic naevus. Small melanocytic naevi typically show an extension along the adnexal structures 
and neurovascular bundles. While pure intradermal melanocytic naevi are rare in the first years of life, 
large congenital melanocytic naevi typically show diffuse extension into the subcutis. Maturation of 
the dermal melanocytic component is invariably present. 
Occasionally, however, a subset of congenital melanocytic naevi in neonates and young adults display 
concerning histological features. They may lead to a mistaken diagnosis of melanoma, especially if 
the age of the patients is unknown. Two such settings are recognized and must not be confused 
with melanoma: an atypical melanocytic proliferation in the epidermis and a proliferation nodule or 
multiple nodules within congenital melanocytic naevi (see below).
Atypical epidermal melanocytic proliferation consists of large and abnormally located junctional 
nests as well as lentiginous and pagetoid proliferation of either single melanocytes or small groups 
of melanocytes. Melanocytes usually display an epithelioid morphology. Cytological atypia is present 
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in up to 30% of cases and is usually mild but may on occasion be severe (1, 10). Junctional mitoses 
can be frequent. Pagetoid proliferation is commonly present at the periphery of the lesion. 
The dermal melanocytic component is usually unremarkable. nevertheless, cytological atypia may 
on occasion be observed in the dermal melanocytic component and is associated with impaired 
maturation. Variation in the amount of melanin pigment in the cytoplasm of melanocytes is 
common (10). Mitotic activity is frequently absent. however, an occasional regular mitosis in the 
superficial dermal melanocytic component should not be regarded as a sign of malignancy.
Differential diagnosis
Malignant melanoma is exceedingly rare in neonates and young children. importantly, however, 
melanoma in congenital melanocytic naevus usually develops within the dermal component 
and not in the epidermis, and shows similar histological features to melanoma in adults, i.e., 
lack of maturation, prominent mitotic activity, including atypical ones, expansile growth and 
pleomorphism of melanocytes.
Proliferative nodule within a congenital naevus
A proliferative nodule within a congenital melanocytic naevus was originally described by Reed 
et al in 1975 and further delineated as a specific entity by Clark et al in 1990 (11, 12). A proliferative 
nodule is defined as a distinctive melanocytic proliferation in the dermis or rarely subcutis that 
develops in the background of a compound, most frequently a congenital melanocytic naevus. 
Although a proliferative nodule uniformly follows a benign clinical course, the histological 
features of this peculiar melanocytic proliferation are worrying and may lead to the incorrect 
diagnosis of an intradermal melanoma. 
Clinical features
A proliferative nodule presents as a smooth surfaced nodule in the background of a congenital 
melanocytic naevus, most frequently although not exclusively within a giant congenital 
melanocytic naevus (13-20). The lesion shows a predilection for the trunk and back, followed by 
the scalp and face. A proliferative nodule is usually already present at birth and shows female 
predominance. Solitary lesions are most frequent but satellite lesions can also be present. On 
occasion, a proliferative nodule may become ulcerated (20). The natural history of proliferation 
nodules is one of spontaneous gradual regression. Alternatively, they can be a stable lesion over 
a prolonged period of time, or exhibit enlargement and hyperpigmentation.
Histological features
A scanning magnification demonstrates a well-defined nodular melanocytic proliferation in the 
superficial and middle dermis (13-20). Much more rarely, the nodule can involve also the superficial 
subcutis. increased cellularity within the nodule, as compared with the background melanocytic 
proliferation, is easily perceived. Although the lesion in the great majority of cases blends at its 
margin with the adjacent ordinary melanocytic proliferation, little or no blending may also be 
seen. A proliferation nodule is composed of epitheliod or spindled melanocytes that are larger 
than the neighboring melanocytes. lesional melanocytes have abundant eosinophilic cytoplasm 
and generally display mild nuclear atypias. intranuclear pseudoinclusions are frequent. nucleoli 
are small and are usually not prominent. Mitoses are rare and regular. Their number is by 
definition less than 1 mitosis per mm2. Atypical mitoses and necrosis within the nodule are not 
a feature of a proliferation nodule. Maturation is present and is most easily found at the site and 
at the bottom of the nodule. Occasionally, greater nuclear pleomorphism and macronucleoli can 
be observed in a proliferation nodule, which is not associated with increased mitotic activity. A 
mild to moderate mononuclear inflammatory cell infiltrate composed of lymphocytes, confined 
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to the proliferation nodule, can be sometimes be present. Epidermal involvement is rare but can be 
present. no pagetoid spread is however seen. Areas of mesenchymal differentiation can occasionally 
be seen within a proliferative nodule. Although proliferation nodules generally show an expansile 
growth pattern with pushing borders, they may on occasion also demonstrate infiltrative but non-
destructive growth, preserving hair follicles and eccrine ducts.
Molecular studies on proliferative nodules have shown either no chromosomal aberrations or have 
demonstrated the presence of numerical anomalies of the whole chromosomes (21, 22). Melanomas generally 
show more complex genetic aberrations, including gains and losses of chromosomal fragments (22).
Differential diagnosis
Main differential diagnosis is with malignant melanoma (see above). distinguishing histological 
features include the lack of uniform high-grade nuclear atypia, lack of necrosis within the nodule, 
rarity of mitoses (less than 1 per square mm) with the absence of atypical mitoses, presence of 
maturation, lack of pagetoid spread and absence of destructive expansile growth (20).
Pagetoid Spitz naevus
Pagetoid Spitz naevus, also designated as intraepidermal Spitz tumour with prominent pagetoid 
spread, is a distinctive melanocytic proliferation originally described by busam and barnhill in 1995 
(23). Pagetoid Spitz naevus is a morphological variant within the spectrum of epithelioid and spindle 
cell melanocytic naevi (e.g. Spitz naevi). it differs from a conventional junctional Spitz naevus by 
proliferation of single epithelioid melanocytes within the epidermis. Such proliferation is generally 
a minor component of a conventional junctional Spitz naevus. The main importance of pagetoid 
Spitz naevus lies in its distinction from melanoma in situ, early invasive melanoma and other non-
melanocytic proliferations with pagetoid growth pattern (see below).
Clinical features
Pagetoid Spitz naevus usually presents as a solitary symmetrical flat or slightly elevated light to dark 
brown macule measuring less than 4 mm in maximum diameter. it shows a predilection for young 
females (mean age about 25 years) and occurs most frequently on the lower extremities (23-25).
Histological features
low power magnification generally demonstrates a well-circumscribed, well-demarcated and usually 
symmetrical proliferation of melanocytes within the epidermis (23-25). by definition, the lesion is 
small in size and is composed of a proliferation of single epithelioid melanocytes. furthermore, the 
morphology of epithelioid melanocytes is fairly uniform within the lesion. Although the single cell 
proliferation of melanocytes is the predominant growth pattern, junctional nests can also on occasion 
be seen. in such instances, melanocytic nests form a minor melanocytic component.
The melanocytes are round, oval or polygonal and have well-defined cell borders. The cytoplasm is 
abundant and glassy. The nuclei of melanocytes are frequently larger than the nuclei of keratinocytes, 
are round to oval, and contain prominent eosinophilic nucleoli. nuclear chromatin is finely granular. 
Each cell is typically separated from the neighbouring cells by a retraction artefact. Although pagetoid 
proliferation is usually limited to the lower half of the epidermis, full thickness pagetoid spread can 
also be present. Mitoses are generally absent. 
Additional changes frequently seen in pagetoid Spitz naevus include acanthosis of the epidermis and 
mild mononuclear inflammatory cell infiltrate composed of lymphocytes and histiocytes within the 
superficial dermis.
Differential diagnosis
The main differential diagnosis includes melanoma in situ. low power examination of melanoma 
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in situ demonstrates an asymmetrical and poorly demarcated melanocytic proliferation that 
usually extends over a larger surface area of the skin. Cytological atypia is non-random, is more 
pronounced and widespread, upward migration of atypical melanocytes is often multifocal. fine 
or dusty melanin pigment and mitoses are also suggestive of melanoma. in addition, melanoma 
in situ frequently shows a nesting pattern of melanocytic proliferation with irregularly sized 
nests, dyscohaesion of nests and their confluence.
non-melanocytic intraepidermal pagetoid proliferations, such as mammary/extrammamary 
Paget’s disease, pagetoid squamous cell carcinoma in situ, sebaceous carcinoma in situ or 
intraepidermal lymphoid proliferations can be distinguished from melanocytic proliferations by 
negative S100 immunohistochemistry.
Note of caution
The diagnosis of pagetoid Spitz naevus in the elderly should always be questioned. if the 
diagnosis of pagetoid Spitz naevus is in doubt, a conservative re-excision is advised to ensure 
complete removal of the lesion.
Recurrent melanocytic naevus
Recurrent melanocytic naevus or so-called Ackerman’s pseudomelanoma is defined as an atypical 
melanocytic proliferation at the site of previous incomplete excision of a benign melanocytic 
naevus (26). Recurrent melanocytic naevus most commonly develops after shave biopsy, but similar 
lesions have also been reported following laser treatment, cryotherapy or local application of 
topical agents (27, 28). nevertheless, it should always be taken into consideration that recurrent 
dysplastic melanocytic naevus or melanoma in situ can mimic a recurrent melanocytic naevus. 
Clinical features
Recurrent melanocytic naevus most commonly develops within 6 months following the initial 
procedure, shows female predominance and most frequently occurs on the back (29). it presents 
clinically as an irregular, variably pigmented macular lesion at the site of a previous procedure 
(26).
Histological features
defining histological features of a recurrent melanocytic naevus are architectural and cytological 
abnormalities restricted to the area above the scar. Abnormalities do not extend beyond this 
area and are usually limited to the epidermis. 
The lesion shows asymmetry, but generally shows good lateral circumscription. lentiginous 
proliferation of individual melanocytes or small groups of atypical melanocytes are seen. in 
addition, focal nesting of melanocytes can also be present. Melanocytes frequently display 
hyperchromatic nuclei. Atypia of melanocytes varies from absent to severe and is most commonly 
mild to moderate (30). focal pagetoid spread of melanocytes is occasionally seen and is usually 
restricted to the central part of the lesion. Mitoses are not present, or are very rare and regular. 
in the dermis, a superficial chronic inflammatory cell infiltrate with numerous macrophages is 
frequently present. A rete ridges pattern overlying the scar is frequently effaced. On occasion, 
however, retiform epidermal hyperplasia confined to the area of the scar can be seen (29).
Residual junctional or more commonly intradermal melanocytic naevus is frequently present in 
association with the scar and shows unremarkable histological features. 
Differential diagnosis
Clinico-pathological correlation is essential, and the previous biopsy, if available, should always 
be reviewed. A diagnosis of recurrent melanocytic naevus can be particularly challenging in the 
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absence of clinical information or slides from the previous biopsy. The most useful distinguishing 
features for recurrent melanocytic naevus are a sharp restriction of cytological and architectural 
abnormalities to the area of the epidermis above the scar, the absence of mitotic activity and the 
presence of the scar in the dermis.
Pseudomelanoma phenomenon has also been reported in a subset of melanocytic naevi, so called 
sclerosing naevi (31). They are characterized histologically by a central area of scar, not related to 
previous procedure or trauma, accompanied by remnants of a naevus at the periphery of the scar. 
Similar to pseudomelanoma phenomenon in recurrent naevi, the epidermal component in sclerosing 
naevi consists of irregularly sized and confluent nests of melanocytes with occasional upward 
extension of melanocytes, confined to the area above the scar. no significant atypia of melanocytes is 
seen and mitoses are absent or scarce. These changes are thought to be related to partial regression 
of the lesion.  
Meyerson’s phenomenon in melanocytic nAevus
Meyerson’s phenomenon is an annular dermatitis or eczema superimposed on a melanocytic lesion. 
it has most frequently been observed in association with an acquired, usually compound naevus 
(32-35). This phenomenon has also been reported, albeit rarely, in congenital melanocytic naevi and 
dysplastic naevi (36-38). The etiology of Meyerson’s phenomenon is at present unknown. Treatment 
with interferon has been implicated in the development of Meyerson’s phenomenon in isolated cases.
Clinical features
Meyerson’s phenomenon in melanocytic naevus presents as an asymptomatic or sometimes pruritic, 
erythematous lesion with a scaly border measuring up to 1.0 cm in diameter. Meyerson’s phenomenon 
shows a predilection for melanocytic naevi located on the trunk and proximal extremities, displays 
a male predominance, and is most commonly seen in the third decade (32, 33). Multiple lesions can 
also be seen. following resolution of the dermatitis, the naevus appears unchanged. Areas of 
hypopigmentation can occasionally be seen.
Histological features
The defining histological features of Meyerson’s phenomenon include parakeratosis, acanthosis 
and spongiosis associated with a superficial perivascular chronic inflammatory cell infiltrate. The 
inflammatory cell infiltrate consists predominantly of Cd4+ lymphocytes, both in the epidermis and 
dermis (36, 37). Eosinophils are sometimes conspicuous. There is no histological evidence of regression.
Similar changes surrounding a diverse range of lesions, including seborrheic keratosis, stucco 
keratoses, keloids, naevus flammeus, squamous cell carcinoma, basal cell carcinoma, and 
dermatofibroma have occasionally been described (40, 41).
Differential diagnosis
Prominent eczematous reaction overlying melanocytic proliferation can obscure the true nature of 
the lesion. it is important to note that superimposed Meyerson’s phenomenon does not change the 
morphology of a melanocytic lesion. Although some degenerative atypias of melanocytes can be 
seen, the mitotic activity of melanocytes remains unchanged. Since such a phenomenon has also been 
reported in dysplastic melanocytic naevi and can be seen in melanoma in situ or invasive melanoma, 
careful evaluation of the underlying melanocytic lesion is of utmost importance.
Halo Naevus
halo naevus was originally described by Sutton in 1916 and designated as leukoderma acquisitum 
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centrifugatum (42). halo naevus is a descriptive designation for a melanocytic naevus showing a 
distinctive clinical feature: a halo surrounding the melanocytic naevus. however, since a clinical halo 
can on occasion be missing, the use of the expression ‘melanocytic naevus with halo phenomenon’ 
has recently been proposed thus referring to the characteristic histological features (10).
The halo phenomenon is the consequence of a prominent immune host response in the dermis, 
which is directed towards melanocytes and eventually results in the regression of the lesion. The 
immune host response can on occasion be so extensive that it obscures the melanocytic nature 
of the lesion. furthermore, lesional melanocytes can display prominent degenerative atypia, 
which may be mistaken for melanoma. Since the halo phenomenon is a non-specific reaction 
pattern, it can be found in a myriad of melanocytic proliferations, such as congenital melanocytic 
naevus, blue naevus, Spitz naevus, dysplastic naevus and even malignant melanoma (43-47).
Clinical features
The halo naevus is characterized clinically by a central macule or slightly elevated brown to dark 
lesion surrounded by a well-circumscribed area of hypopigmentation or depigmentation (48, 49). 
The central area can be covered by scale or crust and have a verrucous appearance, especially 
in children (50). The halo naevus typically presents in the first two decades of life, shows a 
predilection for the trunk, especially back and has an equal sex distribution. The lesions can be 
multiple and occasionally show familial clustering (44, 51-54). Patients with Turner’s syndrome have 
an increased prevalence of halo naevi as compared to the general population (18% vs. 1%) (55).
Histological features
low power magnification can show significant architectural distortion (10). The lesion may be 
asymmetrical due to prominent lymphocytic infiltration.  Melanocytic naevus is most frequently 
compound, and much more rarely purely intradermal or junctional. Junctional nests of melanocytes 
can be obscured by a lichenoid infiltrate. no pagetoid spread of melanocytes is generally seen. 
Cytological atypia is frequently seen in both junctional and dermal melanocytes, is usually mild 
to moderate and degenerative in nature. The dermal melanocytic component shows maturation. 
Mitoses are generally absent. Mitoses in the inflammatory cell component that are mistaken for 
melanocytes are an important diagnostic pitfall. in later stages of the lesion, melanocytes can 
be difficult to identify without additional S100 immunostaining. A completely resolved naevus is 
characterized by epidermal hypopigmentation associated with scattered dermal melanophages. 
Mild scarring may sometimes be evident.
by immunohistochemistry, the majority of lymphocytes are of a suppressor/cytotoxic T-cell 
phenotype, admixed with a minor population of Cd4-positive T helper cells, b lymphocytes, 
macrophages and langerhans’ cells (55-58). Occasional plasma cells can also be seen. Pigment 
containing macrophages can be prominent, especially in the later stages of the lesion.
Differential diagnosis
Malignant melanoma can be distinguished from melanocytic naevus with halo phenomenon by 
the presence of melanoma in situ in the epidermal melanocytic component. furthermore, the 
dermal melanocytic component in melanoma is characterized by non-random cytological atypia, 
the presence of dermal mitoses, lack of maturation, and expansile growth. Additionally, patchy 
inflammatory cell infiltrate and the presence of true regression (e.g., vascular proliferation, 
fibrosis) is also suggestive of melanoma.
Combined melanocytic naevus
Combined melanocytic naevus is defined histologically as a melanocytic naevus harbouring two or 
more distinct populations of melanocytes within a single lesion. A new designation, ‘melanocytic 
92
naevus with phenotypic heterogeneity’, has recently been proposed for such melanocytic lesions (10). 
Accordingly, a combined melanocytic naevus can display any combination of common melanocytic 
naevus (common acquired naevus, congenital naevus and dysplastic naevus), blue naevus (common, 
cellular and deep penetrating) and/or Spitz naevus (conventional or desmoplastic). 
Clinical features
Clinical features of a combined melanocytic naevus can be unusual and concerning. A combined 
melanocytic naevus presents as a flat or eccentrically raised macule or papule showing variegated 
pigmentation. Sex distribution is equal and the lesion shows a predilection for the trunk, followed by 
head and neck, upper and lower extremity, perineum and buttocks (59). Combined melanocytic naevi 
have also been described at mucosal sites. 
Histological features
The combination of deep penetrating naevus and common acquired melanocytic naevus appears to 
be the most frequent association (59-61). The cells of the common naevus generally occupy the upper 
part of the lesion, including the junctional component. Although different components are usually 
relatively well separated from each other, they may also be intermixed, thus making distinction 
between different melanocytic populations difficult (for example, common or cellular blue naevus 
and deep penetrating naevus).
Differential diagnosis
Careful examination of the lesion will demonstrate different melanocytic populations with distinctive 
histological features. importantly, a lack of maturation can be seen in a subset of blue naevi (cellular 
and deep penetrating naevi). in addition, occasional regular mitoses in the dermal melanocytic 
component are not uncommon. Atypical mitoses are, however, not a feature in combined melanocytic 
naevi.
Malignant melanoma can be distinguished by the presence of melanoma in situ in the junctional 
component. Pure intradermal melanomas are rare and metastatic melanoma must be ruled out in 
such instances. The dermal melanocytic component usually demonstrates nuclear pleomorphism, an 
expansile growth pattern and mitoses, including atypical ones.
Deep penetrating naevus
deep penetrating naevus may simulate melanoma both clinically and histologically. One or more 
disturbing histological features can frequently be found in deep penetrating naevus, and include 
asymmetry, plump but fairly regular nests of melanocytes in the dermis, cytologic atypia with nuclear 
pleomorphism, somewhat prominent eosinophilic nucleoli, an absence of maturation, the occasional 
presence of regular dermal mitoses and a patchy mononuclear inflammatory cell infiltrate. Although 
unusual, such histological features should not be regarded as a sign of malignancy in deep penetrating 
naevus. deep penetrating naevi, on the basis of lack of maturation, prominent pigmentation, growth 
along neuro-vascular bundles and skin adnexa, and occasional presence of dendritic cells, have been 
regarded as a variant of a blue naevus (62, 63). however, the exact histogenesis of deep penetrating 
naevus has not to date been elucidated.
deep penetrating naevus is a distinctive melanocytic naevus originally described by Seab et al in 
1989 (64). A plexiform spindle cell naevus subsequently reported by barnhill et al has essentially the 
same histological features (65, 66). in addition, a superficial variant of deep penetrating naevus lacking a 
deep penetrating component has been designated melanocytic naevus with focal atypical epithelioid 
components or clonal naevus (67, 68). Although the name ‘deep penetrating naevus’ implies extension 
into the deep dermis or subcutis, it is rather the combination of growth pattern and cell morphology 
that define the entity. 
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Clinical features
deep penetrating naevus generally presents in the third decade of life as a solitary papule or 
nodule of less than 1 cm in the diameter, and shows a slight female predominance (f:M=1.3:1) 
(60, 61, 64, 65, 68, 69). less than 5% of deep penetrating naevi develop after the age of 50 years. A 
diagnosis of a deep penetrating naevus in elderly patients should be made with caution, e.g., by 
excluding a deep penetrating naevus-like melanoma (see below). 
The duration of the lesion prior to excision has been from recent development to several years 
and a congenital occurrence has also been documented (60, 61). Pigmentation can be variegated, 
from light brown to black, but most lesions are darkly pigmented. Especially if a part of a 
combined melanocytic naevus, the lesion may appear asymmetrical and unevenly pigmented, 
thus raising the clinical suspicion of melanoma. The most frequent site of origin is the skin of 
the head and neck, followed by the extremities and trunk. deep penetrating naevus has not 
been described on the palms and soles.
Histological features
The distinctive morphological features of a deep penetrating naevus can already be perceived 
with scanning magnification. deep penetrating naevus is sharply demarcated, well circumscribed, 
often symmetrical and usually shows a wedge shaped configuration of the lesion with the base 
towards the epidermis and the tip towards the reticular dermis/subcutis (62). frequently, however, 
one or more extensions along the skin adnexa or neuro-vascular bundles into the deep reticular 
dermis and/or subcutis are seen, giving the lesion a plexiform appearance. 
A limited junctional melanocytic component is present in 60-85% of deep penetrating naevi 
(60,61,64,64,68,69). The epidermal melanocytic component consists of lentiginous proliferation 
and nests of melanocytes with uniform round to oval nuclei, indistinct nucleoli and scarce 
to moderately abundant cytoplasm containing mild to moderate amounts of melanin. focal 
pagetoid proliferation of uniform melanocytes into the uppermost layers of the epidermis has 
been very rarely reported in deep penetrating naevi (61) but this feature is exceptionally found 
and should prompt careful scrutinizing of the lesion to exclude melanoma.
The papillary dermis is frequently not involved, thus representing a tumour-free zone between 
the junctional melanocytic component, if present, and the melanocytic proliferation in the 
reticular dermis and subcutis. discontinuity of the lesion in the papillary dermis, if present, 
may be a useful histological feature in excluding melanoma, which usually grows in continuity 
between the epidermis and the dermis.
The dermal component, usually located in the reticular dermis, consists of loose nests and 
vertically oriented fascicles of epithelioid cells and short spindle-shaped melanocytes. While 
the epithelioid morphology is more frequent in upper parts of the lesion, the spindle cell 
morphology may predominate in the deeper parts. The epithelioid cells differ from those seen in 
common acquired melanocytic naevi by displaying more abundant cytoplasm and larger nuclei. 
The proportion of both epithelioid and spindle-shaped components can vary greatly within 
and among the lesions. A confluence of nests may be seen, especially in the upper dermis and 
central areas of the lesion but is usually a focal feature. discohesion of melanocytes is usually 
present at the periphery and bottom of the lesion, where melanocytes are seen splaying collagen 
fibres. Melanocytes grow along skin adnexa and neuro-vascular bundles without destroying 
them. Perineural extension is a common feature. infiltration of the arrector pili muscle is a 
frequent occurrence in deep penetrating naevi.
Cytologically, melanocytic nuclei are hyperchromatic, with variation in their size and shape 
from round to oval. nuclear contours may be irregular. Mild to moderate nuclear pleomorphism 
is a constant feature in deep penetrating naevi and may be focally marked, with the size of 
melanocytic nuclei being more than twice the size of basal keratinocytes. Considerable variation 
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in the size of the nuclei can also be observed within individual melanocytic nests and/or fascicles. 
no obvious maturation of melanocytes is seen. Cytoplasmic nuclear (pseudo)inclusions can usually 
be found. nucleoli are small to medium sized and eosinophilic. Mitoses can be present, even in the 
deeper parts of the naevus. Their number ranges from 0-1.2 per mm2 (60, 61). Proliferative activity in 
deep penetrating naevi is present in fewer than 5% of dermal melanocytes (70). Atypical mitoses are 
not found and their presence should arouse the suspicion of melanoma. Melanocytes have moderate 
to abundant cytoplasm, which is lightly to moderately pigmented. Areas of clear cell change within 
deep penetrating naevi are common.   
Other constant morphological components in deep penetrating naevi are melanophages and a 
mononuclear inflammatory cell infiltrate. Melanophages can be sparse and focal to abundant and 
dispersed throughout the lesion. They usually surround individual nests and bundles of melanocytes 
and are especially prominent at the periphery of the lesion. A mononuclear inflammatory cell 
infiltrate, composed predominantly of mature lymphocytes can be sparse and focal or prominent 
and diffuse, a pattern reminiscent of ‘tumour infiltrating lymphocytes’ in melanomas. in a subset of 
deep penetrating naevi, scattered pigmented dendritic melanocytes can be seen and, in this context, 
distinction from a variant of blue naevus may be difficult and has prompted some to suggest that 
deep penetrating naevus is part of the spectrum of blue naevus. 
‘Atypical’ histological features in deep penetrating naevi
One or more histological features can frequently be found in deep penetrating naevi, which may 
cause concern as to the biological potential of the lesion. These include asymmetry of the lesion, 
expansile melanocytic nests in the dermis, random cytological atypia with nuclear pleomorphism, 
prominent eosinophilic nucleoli, absence of maturation, presence of dermal mitoses and mononuclear 
inflammation. Although unusual, such histological features are expected to be seen in about 40% of 
deep penetrating naevi and should not be regarded as a sign of malignancy (61). Random cytological 
atypia, with individual nuclei displaying enlargement and hyperchromatism, is present in a number 
of cases, particularly in younger individuals. This is not usually associated with an increase in mitotic 
activity. 
Melanocytic naevus with focal atypical epithelioid component (clonal 
naevus) – a superficial variant of deep penetrating naevus
in 1994, ball and golitz described a series of 73 cases of a peculiar melanocytic naevus, characterised 
histologically by poorly circumscribed small groups or nests of large, deeply pigmented epithelioid 
melanocytes located in the superficial dermis, developing in the background of an ordinary 
melanocytic naevus (67). These melanocytes were distinguished by irregular nuclear contours, small 
nucleoli and prominent cytoplasm containing melanin. Mitoses were absent or extremely rare. 
nests of melanocytes were surrounded by deeply pigmented melanophages. Subsequent study has 
confirmed that melanocytic naevi with focal atypical epithelioid component share a similar age and 
anatomic distribution with deep penetrating naevi (68). furthermore, cytological features between the 
two entities were essentially identical - the only difference between the two entities being the depth 
of extension of the epithelioid component (68). Melanocytic naevus with focal epithelioid component 
has therefore been regarded as a superficial variant of a deep penetrating naevus.
Biological potential and treatment
deep penetrating naevus is a benign melanocytic proliferation. in reviewing the literature of more 
than 300 deep penetrating naevi published to date, only three local recurrences following incomplete 
excision have been reported (60, 68). Conservative and complete local excision appears to be the best 
treatment option for deep penetrating naevi.
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Differential diagnosis
The main differential diagnosis is with melanoma. Primary cutaneous melanoma is an asymmetrical 
and poorly circumscribed proliferation of melanocytes with a junctional component comprising 
lentiginous and/or pagetoid proliferation of atypical melanocytes with destructive growth in 
the dermis. discontinuity of the lesion in the papillary dermis, as frequently observed in deep 
penetrating naevi, is generally not seen in melanomas. The dermal melanocytic component 
in melanomas consists of expansile nests or sheaths of atypical melanocytes. Cellular atypias 
in melanomas are more pronounced than in deep penetrating naevi and are non-random in 
distribution. furthermore, mitoses in melanomas are frequent, including atypical forms. Mitoses 
can also be observed in the deeper parts of the lesion. Metastatic intradermal melanoma can be 
separated from deep penetrating naevus by a wedge shaped configuration, symmetry and lack or 
very limited mitotic activity with absence of atypical mitoses of the latter. Pigment synthesizing 
melanoma is characterised by dome shaped proliferation of heavily pigmented epithelioid and 
spindle melanocytes with abundant cytoplasm, large vesicular nuclei and prominent nucleoli. 
nuclear pleomorphism is usually apparent, mitoses can be found and also include atypical ones. 
Melanocytes show variable extension along the skin adnexa but also show more diffuse and 
destructive growth in the dermis, with frequent infiltration into the subcutis. The junctional 
component in pigment synthesizing melanomas, if present, is commonly dendritic.
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CASE 1.  A 60-year-old male with slowly growing polypoid lesion on the 
upper thigh
Diagnosis: Cutaneous (intradermal) clear cell sarcoma
References
- Enzinger fM., Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases, Cancer 1965; 18: 1163-1178;
-  Reeves bR, fletcher Cd, gusterson bA., Translocation t(12;22)(q13;q13) is a nonrandom rearrangement in clear cell sarcoma, 
Cancer genet Cytogenet 1992; 64: 101-103
-  hantschke M et al., Cutaneous Clear Cell Sarcoma: A Clinicopathologic, Immunohistochemical, and Molecular Analysis of 12 
Cases Emphasizing its Distinction from Dermal Melanoma, Am J Surg Pathol 2010; 34: 216-222
-  falconieri g et al., Cutaneous Clear Cell Sarcoma: Report of Three Cases of a Potentially Understimated Mimicker of Spindle 
Cell Melanoma, Am J dermatopathol 2012; 34:619-625.
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CASE 2. A 21-year-old female with a nodule on the nose
Diagnosis: Cellular neurothekeoma
References
- gallager Rl, helwing Eb., Neurothekeoma – a benign cutaneous tumour of neural origin. Am J Clin Pathol 1980; 74: 759-764.
-  hornick Jl, fletcher CdM. Cellular neurothekeoma: detailed characterization in a series of 133 cases., Am J Surg Pathol 2007; 
31: 329-40
-  Fetsch, JF et al. Neurothekeoma: An Analysis of 178 Tumors With Detailed Immunohistochemical Data and Long-term 
Patient Follow-up Information, Am J Surg Pathol 2007; 31: 1103-1114
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CASE 3.  A 69-year-old male with the lesion on the scalp.  
Clinical diagnosis: scar
Diagnosis: Desmoplastic melanoma
References
-  Conley J, lattes R, Orr William, Desmoplastic Maligmant Melanoma (a Rare Variant of Spindle Cell Melanoma), Cancer 1971; 
28: 914-936
-  Reed R, leonard d, Neurotropic Melanoma. A variant of desmoplastic melanoma. Am J Surg Pathol 3: 301-311, 1979.
-  busam k et al., Cutaneous Desmoplastic Melanoma. Reappraisal of Morphologic Heterogeneity and Prognostic Factors, Am 
J Surg Pathol 2004;28:1518-1525).
-  george et al., Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities 
for lymph node metastasis,  J Cutan Pathol 2009; 36: 425-432.
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CASE 4. A 62-year-old male with the lesion on the upper arm
Diagnosis: PEComa (Perivascular epithelioid cell tumour)
References
- liegl et al. Primary Cutaneous PEComa: Distinctive Clear Cell Lesions of Skin., Am J Surg Pathol 2008; 32: 608-14
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CASE 5. A 74-year-old male with the lesion on the scalp.
Diagnosis: Atypical fibroxanthoma
References
-  helwig Eb. Atypical fibroxanthoma. In: Seminar Proceedings of 18th Annual Seminar of San Antonio Society of Pathologists, 
1961. Tex State J Med. 1963; 59: 664-667.
-  Calonje E. et al., Spindle-cell non-pleomorphic atypical fibroxanthoma: analysis of a series and delineation of a distinctive 
variant., (1993) histopathology 22, 247-254.
-  luzar b, Calonje E., Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special 
emphasis on potential diagnostic pitfalls., J Cutan Pathol. 2010;37:301-309
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CASE 6.  A 21-year old woman in the 6 month of pregnancy with an atypical 
pigmented lesion on the vulva. Clinical diagnosis: melanoma
Diagnosis: Atypical compund genital melanocytic naevus
References
-  Quddus M, Atypical melanocytic nevi of genital type: A distinctive pigmented lesion of the genital tract often confused with 
malignant melanoma., dermatology Online Journal 16 (2): 9
-  Xu X, Elder d, A Practical Approach to Selected Problematic Melanocytic Lesions., Am J Clin Pathol 2004;121(Suppl 1):S3-S32
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Update on pathology of Pulmonary Hypertension
Pulmonary hypertension (Ph) is a haemodynamic and pathophysiological state that can be found in multiple 
clinical conditions (more than thirty). These have been grouped in six clinical categories in accordance with 
the underlying clinical condition.
group 1 Ph or Pulmonary Arterial hypertension (PAh) brings together diseases sharing characteristic 
pathologic lesions: sustained pulmonary vasoconstriction, lumen obliteration of small and medium size 
arteries and arterioles in association with the formation of plexiform lesions and in situ thrombosis, as 
well as concentric thickening of pulmonary arteries resulting from intimal fibrosis and medial hypertrophy. 
This structural damage of pulmonary arteries provokes an increase in pulmonary vascular resistance, right 
ventricular overload and finally right heart failure.
PAh is an infrequent disease having an estimated incidence around 2.4 cases/million adult population/year 
and prevalence between 15 and 50 subjects per million habitants.
detection and diagnosis of PAh is frequently delayed for 2 or 3 years with important implications on 
patients’ outcome. its historical poor prognosis has been changing in the last decades with the discovery 
of new drugs and strategies for its treatment. Early detection and aggressive goal oriented therapy have 
brought improvements in the functionality, quality of life and survival of these patients.
PAh clinical management is complex and costly reason why patients must be oriented and managed in 
dedicated referral centres integrating a well-regulated national network.      
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Overview of Pleural Mesothelioma
Malignant Mesothelioma
Although relatively infrequent, mesothelioma is the most common malignant tumor in the pleura but also 
the one that poses more difficulty in the diagnosis due its varied histopathological appearance and related 
medicolegal issues. Their incidence in the united States is of approximately 3 to 7 cases per million persons 
in the population per year, and 15-20/million worldwide.  Although mesotheliomas have been associated 
to the exposure of asbestos fibers, approximately 50% of individuals affected by mesotheliomas do not 
disclose an asbestos exposure, nonetheless a multifactorial etiopathogenetic mechanism may be claimed. 
in general mesotheliomas are more common in adult individuals the fifth-sixth decade.  in those cases 
in which the tumor is associated with asbestos, the patient had been exposed for over 15 years to the 
asbestos fibers. it would be very unusual to find a case in which the tumor is linked to asbestos in a patient 
with only a few years of exposure.  
Clinical Features 
Clinical and radiological information play a highly important role in the diagnosis of mesothelioma.  One of 
the most important aspects in the diagnosis of mesothelioma is the radiological evaluation, either a plain 
chest radiograph or more sophisticated studies such as computerized tomography. The following aspects 
should be inquired in cases suspicious of mesothelioma: nodular studding of pleura, diffuse thickening 
of pleura, encasement of the lung, unilateral or bilateral pleural involvement. Many times the clinical and 
radiological aspects of the cases are clear but the available material for histopathological examination is not 
enough to render a diagnosis of mesothelioma.  in such circumstances, one should not commit him/herself 
but rather raise the level of suspicion and request additional material if clinically indicated.  The rationale 
is the fact that the surgical treatment for cases of mesothelioma can be very radical (i.e. extrapleural 
pneumonectomy), thus, the pathologist must  be absolutely sure about the diagnosis.  in addition current 
chemotherapy protocols are of questionable efficacy, hence delays in diagnosis are not as detrimental to 
patients as in other malignancies. furthermore, it is well known that there are other pleural conditions of an 
inflammatory nature that may clinically and radiologically mimic malignant mesothelioma.  Therefore, one 
should use the clinical and radiological information not to make a diagnosis per se but rather to orient one 
self in the plan to follow with the use of immunohistochemistry and/or electron microscopy.  ultimately the 
diagnosis of mesothelioma is a pathological one and not a clinical or radiological diagnosis alone.
Pathological Features
Macroscopically mesotheliomas are tumors with a characteristic gross appearance. The tumor are most often 
diffuse though in some cases the neoplastic growth follows the intrapulmonary septa; in rare instances 
the tumor may involve the outer lung tissue subjacent the pleura. however, the presence of a well defined 
tumor mass in the periphery, even if the tumor also shows diffuse pleural involvement, should alert about 
the possibility of a peripheral lung cancer with diffuse pleural spread (i.e. pseudomesotheliomous cancers)
Histopathologic characteristics: Mesotheliomas may show several microscopical patterns.  however, traditionally 
mesotheliomas have been divided into three categories: Epithelial, Sarcomatoid, biphasic (combination of 
epithelial and sarcomatoid).
A. Epithelial mesothelioma is in our experience the most common variant. in addition to the classic 
tubulopapillary form, additional variants include the epithelioid, deciduoid, clear cell, glandular , or rarely 
the myxoid or adenomatoid subtypes. The variants of epithelioid mesothelioma are relatively uncommon 
and represent diagnostic challenges. 
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Special Studies
immunohistochemistry has virtually replaced histochemistry and is the most used and often abused 
ancillary technique.  Probably, in not so many field of surgical pathology immunohistochemistry 
of mesothelioma has been the subject of so many published studies, in particular addressing the 
positive identification of mesothelioma cells. Other studies have attempted at the recognition 
of adenocarcinoma as to properly rule out the presence of mesothelioma.  Thus, the diagnosis of 
mesothelioma has in the past been considered one of exclusion.  Many antibodies have been stated to 
be helpful in the diagnosis of mesothelioma, the fact is that only a few are use in practice.  Currently, 
the most popular markers include keratin broad spectrum, keratin 5/6, calretinin, leu-M1, CEA, 
b72.3, and ber-ep4.  Some of those markers have been stated to positively stain mesothelial cells 
(keratin 5/6 and calretinin) while other have been stated to identify cases of adenocarcinoma (CEA, 
leu-M1).  in the setting of an epithelial mesothelioma these markers are more important.  however, 
their positive staining does not constitute a full proof diagnosis of the tumor.  for instance, depending 
on the antibody use, it may alter the interpretation of it.  One of those cases is CEA, which has been 
demonstrated to show some positivity in about 5% of cases of mesothelioma.  however, it is possible 
that this phenomenon may be explained by the use of unabsorbed heteroantisera to CEA.  The use 
of monoclonal CEA appears to be more reliable in this evaluation.  in short, we can summarize the 
immunohistochemical studies in the following manner: if the tumor in question shows positive for 
either of these antibodies - broad-spectrum keratin, keratin 5/6, and calretinin, then the most likely 
interpretation is that of mesothelioma.  however, if there is positive staining for either CEA, le-M1, 
b72.3 or other carcinomatous epitope, then the diagnosis should lean more towards adenocarcinoma
Differential Diagnosis
in the setting of an atypical epithelial cellular proliferation the most important conditions to  establish 
that it is malignant first, the next step being the assessment of tumor cell origin. The single, most 
reliable microscopic criteria is the documentation of tumoral infiltrate in the adipose or soft tissue of 
the chest wall or the subpleural pulmonary tissue. As a corollary, in superficial biopsy fragments the 
diagnosis of mesothelioma should not be rendered with certainty as long as mesothelial hyperplasia 
may not be ruled out.  in addition, cellular proliferation in surface, granulation tissue and fibrin should 
prompt a diagnosis of reactive/inflammatory lesion.  Mitoses and atypia may be observed in both 
mesothelioma and reactive hyperplasia, hence are not useful morphologic criteria. if one has concluded 
that the cellular proliferation in question is malignant, then the use of immunohistochemical studies, 
namely the use of the above listed carcinomatous antibodies is the next step.  Similar steps are adequate 
in the event of a metastatic epithelial neoplasm from other source to the pleura.  
B. Sarcomatoid Mesothelioma:  this variant of mesothelioma is less common than the epithelial one 
and probably represents less than 15% of all these tumors in its pure form, however it poses more 
diagnostic challenges.  The tumor characteristically has a growth pattern of spindle cells with an 
elongated nuclei and inconspicuous nucleoli and mimicks a sarcoma of soft tissues.  A fibrous, 
sometimes collagenized ground substance may be observed as in desmoplastic variant of spindle cell 
mesothelioma. in rare instances, metaplastic bone or cartilage forming tumors have been described. 
Another variant is the so called lymphohistiocytoid where the neoplastic cells are enmeshed in a 
lymphoid cell rich stroma. The desmoplastic is probably the most difficult to be correctly recognized 
since it can simulate a fibrous pleuritis or a scarring process. Clue to malignancy are necrosis, cellular 
atypia, mitotic activity with atypical mitoses, stromal and especially adjacent soft tissue invasion. 
Abrupt transition from acellular to cellular areas featuring spindle cells is a useful clue to spindle 
cell mesothelioma, whereas an inflammatory cellular gradient with granulation tissue haphazardly 
admixed to fibrin and inflammatory cells speak in favor of pleuritis/inflammation. Another issue 
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would be to rule out either a sarcomatoid carcinoma with extension into the pleura or a sarcoma of soft 
tissue.  The presence of an atypical spindle cell proliferation with stromal invasion and necrosis is usually 
a good sign of a sarcomatoid mesothelioma. in desmoplastic mesothelioma however the diagnosis can 
be very difficult when small biopsy fragments are available.  in these cases, the pleural biopsy may show 
more collagenization and only a paucicellular proliferation which may not show marked cytologic atypia; in 
these cases, the diagnosis may not be apparent and one can only make such suggestion if the clinical and 
radiological findings are in keeping with such diagnosis.  
Immunohistochemical studies: in the setting of a spindle cell mesothelioma whether the tumor is desmoplastic 
or not, the role of immunohistochemistry is relatively limited since most of the antibodies use in regular 
epithelial mesotheliomas have no practical use in sarcomatoid mesotheliomas.  The use of broad- spectrum 
keratin is by far the most important of them.  Calretinin may be positive, however synovial sarcoma – the 
most common intrathoracic spindle cell sarcoma – may positively react for calretinin. keratin antibodies 
have some uselfulness in demostrating positivity of fibroblast-like tumor cells that infiltrate the chest wall 
soft tissue in cases of desmoplastic or spindle cell mesothelioma.
Differential Diagnosis
in cases in which there is no doubt about the neoplastic nature of the tumor, the most important differential 
diagnosis is with another spindle cell neoplasm of mesenchymal origin.  in this case, the use of proper 
immunohistochemical studies and/or electron microscopy will lead to amore appropriate interpretation. 
however proper clinicopathologic correlation are of great value. in doubtful cases, again, the pathologist 
is advice to render a provisional microscopic interpretation and if possible ask for more representative 
diagnostic material. 
C. Biphasic Mesotheliomas: these neoplasms feature a mixture of epithelial and sarcomatoid areas. One 
important differential diagnosis with biphasic mesotheliomas is the fact that primary synovial sarcomas of 
the pleura have been described.  however, in that setting the tumor is a pleural-based mass without diffuse 
involvement of the pleura.  Once again, close clinical and radiological correlation is highly advised in that 
setting.
selected references
-  bedrossian CMW, bonsib S, Moran CA. differential diagnosis between mesothelioma and adenocarcinoma: a multimodal 
approach based on ultrastructure and immunohistochemistry. Sem diagn Pathol 1992; 9:124.
-  borow M, Conston A, livornese l, et al. Mesothelioma following exposure to asbestos: a review of 72 cases.  Chest 1973; 
64:641-646.
-  Craighead JE.  The epidemiology and pathogenesis of malignant mesothelioma.  Chest 1989; 96:92-93.
-  grundy gW, Miller RW. Malignant mesothelioma in childhood: report of 13 cases.  Cancer 1972; 30:1216-1218.
-  henderson dW, Attwood hd, Constance TJ, Shilkin kb, Steele Rh. lymphohistiocytoid mesothelioma: a rare lymphomatoid 
variant of predominantly sarcomatoid mesothelioma. ultrastructural Pathology 1988; 12:367-384.
-  hinds MW. Mesothelioma in the united States: incidence in the 1970s. J Occupational Med 1978; 20:469-471.
-  huncharek M, kelsey k, Mark EJ, et al.  Treatment and survival in diffuse malignant pleural mesothelioma: a study of 83 
cases from Massachusetts general hospital.  Anticancer Research 1996; 16:1265-1268.
-  koss Mn, Travis Wd, Moran C, hochholzer l. Pseudomesotheliomatous adenocarcinoma: a reappraisal.  Sem diagn Pathol 
1992; 9:117-123.
-  Moran CA, Wick MM, Suster S.  The role of immunohistochemistry in the diagnosis of malignant mesothelioma.  Sem diagn 
Pathol 2000; 17:178-183.
-  Ordoñez ng, Mackay b. Clear cell mesothelioma.  ultrastructural Pathology 1996; 20:331-336.
-  Ordoñez ng. Epithelial mesothelioma with deciduoid features: report of four cases.  Am J Surg Pathol 2000; 24:816-823.
-  Peterson JT, greenberg dS, buffler PA.  non-asbestos related malignant mesothelioma. A review.  Cancer 1984; 54:951-
960.
-  Wick MR, Moran CA, Mills SE, Suster S.  immunohistochemical differential diagnosis of pleural effusions with emphasis on 
malignant mesothelioma.  Current Opinion in Pulmonary Medicine 2001; 7:187-192.
-  Wright WE, Sherwin RP.  histological types of malignant mesothelioma and asbestos exposure.  br J industrial Med 1984; 
41:514-517.
-  Yousem SA, hochholzer l. Malignant mesothelioma with osseous and cartilaginous differentiation. Arch Pathol lab Med 
1987; 111:62-66.
109
Thymic carcinoma: update of current diagnostic 
criteria and histologic types
giovanni falconieri, M.d.
Thymic carcinoma is histologically defined as a primary thymic epithelial neoplasm showing overt 
cytologic features of malignancy with absence of the organotypical features of differentiation of the 
thymus.  Since histology of thymic carcinoma is largely non-specific, the criteria for making this 
diagnosis should be, in the majority of instances, based on a combination of clinical and morphologic 
data. if a few cases are excepted, the diagnosis of thymic carcinoma cannot be established based 
solely on histopathologic examination. The role of histologic examination is mainly to confirm a 
diagnosis of malignancy (i.e., establish the presence of overt cytological atypia) and to specify the 
morphologic type of the lesion (i.e., squamous, basaloid, lymphoepithelioma-like, sarcomatoid, etc). 
it cannot be over-emphasized that there is nothing distinctive or pathognomonic about the histology of thymic 
carcinoma that can help establish a definitive diagnosis based solely on histologic examination of a 
biopsy or resected specimen. Accurate clinical and instrumental studies are needed to demonstrate 
the absence of an occult tumor elsewhere or to elicit a history of a remote primary. in a number of 
cases, the answer to this question may only be determined by means of a post-mortem examination. 
important exceptions to this rule include cases in which obvious transitions with preexisting thymic 
epithelium or with well-differentiated areas displaying the conventional organotypical features of 
a preexisting thymoma are demonstrated or when dealing with some variants of thymic carcinoma 
whose features are so highly distinctive that origin from an alternate source other than the thymus 
would be highly unlikely, such as basaloid carcinoma of the thymus with cystic changes or carcinoma 
of the thymus with rhabdomyomatous cells.
Histopathologic types
Thymic carcinoma have a broad spectrum of microscopic features. A large number of histologic types 
of thymic carcinoma have been described, virtually identical to similar tumors arising in other organs. 
Phenotypically, thymic carcinomas range from that of low-grade, well-differentiated neoplasm, to a 
high-grade poorly-differentiated malignancy. A common feature of all thymic carcinomas is the fact 
that they lack any of the organotypical features of thymic differentiation (i.e., lobulation separated 
by broad fibrous bands originating from the capsule, perivascular spaces, areas of “medullary” 
differentiation, and a dual cell population composed of immature T-lymphocytes and thymic epithelial 
cells). When present, the lymphoid component in these tumors is made up of either mature T-cells 
or b-lymphocytes/plasma cells.  The most common form of thymic carcinoma in Western patients is 
poorly-differentiated, non-keratinizing squamous cell carcinoma. Primary neuroendocrine carcinomas 
of the thymus are a special category that, although belonging in the same family of tumors, deserve 
special attention and will not be covered in this presentation.
 
Squamous cell carcinoma (SCC) of the thymus
Primary SCC of the thymus can manifest in three forms depending on their degrees of differentiation: 
well-differentiated (keratinizing) SCC; moderately-differentiated SCC, and poorly-differentiated (non-
keratinizing) SCC which is by far the more prevalent in western countries. The latter often shows a 
distinctive syncytial growth pattern along to a heavy lymphoplasmacellular stromal infiltrate, and for 
that reason it was also called “lymphoepithelioma-like” carcinoma, resembling the homonymic lesion 
in nasopharynx.  SCC is the most common type of thymic carcinoma. Most cases occur in middle aged 
adults with a slightly increased female ratio, presents as an anterior mediastinal mass, usually invades 
adjacent structures. lymph node metastases are frequent.
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-  Well-differentiated, keratinizing SCC shows is fully comparable to its common counterpart in other 
organs. The cardinal microscopic features are usually present: nests or cords of large, atypical 
polygonal tumor cells showing a pavement-like, epidermoid arrangement, with large, vesicular nuclei 
with prominent eosinophilic nucleoli and mitoses. Thick cell membranes, intercellular bridges, foci of 
keratinization and squamous pearl formation are commonly identified. focal necrosis may be present. 
SCC is widely invasive and tumor infiltration is associated with a desmoplastic stroma, along to an 
inflammatory infiltrate featuring neutrophils, eosinophils or lymphocytes. Cases exhibiting transitions 
with areas bearing the features of organotypical or atypical thymoma have been published. Rarely, 
association with multilocular thymic cysts has been described as well. The main differential diagnoses 
include a metastasis of SCC to mediastinal lymph nodes and atypical thymoma (WhO type b3 thymoma). 
distinction of these tumors from atypical thymoma can be sometimes difficult. in fact, it is likely 
that many of the cases reported as well-differentiated SCC of the thymus in the literature actually 
correspond to atypical thymomas. The main distinguishing features between these two entities include 
the extensive, as opposed to focal nature of the keratinizing areas in SCC, and the demonstration of 
immature T-lymphocytes intimately admixed with the epithelial tumor cells in atypical thymoma. 
The possibility that well-differentiated SCC of the thymus arises as a result of tumor progression 
from atypical thymoma is supported by the frequent areas of transition observed between these two 
neoplasms and the overlap in histologic features that both can display. This could also explain the 
much more favorable prognosis of well-differentiated thymic carcinoma, which closely parallels that 
of atypical thymoma.
-  Moderately-differentiated SCC is characterized by more pronounced cytologic atypia and less obvious 
evidence of squamous differentiation; the cells display a higher nuclear-to-cytoplasmic ratio, frequent 
mitoses and loss of clear-cut intercellular bridges. keratinization is also focal and inconspicuous and 
keratin pearls are generally absent. Many of the tumor cells display single cell keratinization, with 
brightly eosinophilic cytoplasm surrounding small piknotic or degenerating nuclei. Areas of necrosis 
are more prominent than in the well-differentiated tumors and may be often confluent. lymphovascular 
invasion is also commonly seen. Some tumors can show prominent peripheral palisading of tumor 
cells around small tumor islands. The most important differential diagnosis is with a metastasis from 
a SCC of the lung. This distinction is of clinical importance since primary squamous cell carcinoma of 
the thymus follows a better prognosis than a comparable primary squamous cell carcinoma of the lung 
with mediastinal lymph node involvement. in Shimosato et al series, cases in which the primary thymic 
tumors could be successfully excised and treated with postoperative radiation the patients were alive 
and well from 1-12 years after diagnosis. A careful clinical approach which includes bronchoscopic 
examination and detailed instrumental studies are recommended to demonstrate absence of bronchial 
compromise in such tumors and to rule out the possibility of massive mediastinal extension from a 
pulmonary primary lesion. 
-  Poorly-differentiated (non-keratinizing) SCC is characterized by sheets and islands of primitive-
appearing round to oval tumor cells with large, vesicular nuclei, prominent, often centrally 
placed eosinophilic nucleoli, and scant rim of pale cytoplasm with indistinct cell borders. foci of 
keratinization are rarely seen and intercellular bridges are always absent. The tumors often grow in 
a syncytial pattern separated by a dense lymphoid stroma closely reminiscent of the nasopharynx 
analogue lesion. Snover et al originally addressed the resemblance of these tumors with their 
nasopharyngeal counterpart; hence the “lymphoepithelioma-like carcinoma” appellation. The latter 
term, however, is somehow obsolete and is no longer used to refer to the nasopharyngeal tumors; 
it is therefore probably best abandoned. A striking and distinctive feature of these tumors is foci of 
central, comedo-like areas of necrosis within the tumor cell islands. On higher magnification, the 
tumor cells often display high mitotic activity (>10 mitoses x 10/hPf). The intervening stroma often 
displays a heavy lymphoplasmacellular infiltrate, however many tumors may be associated with a 
desmoplastic stroma devoid of lymphoid elements. The clue to the diagnosis lies in the identification 
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of the characteristic nuclear morphology featuring large vesicular nuclei with scant chromatin 
and centrally placed round eosinophilic nucleoli. Association with a preexisting thymoma has 
also been well-documented. in particular, a close relationship with spindle cell thymoma (WhO 
type A thymoma) has been observed raising thus the possibility that some cases may arise 
from transformation of spindle cell thymoma. Another association observed for these tumors 
is with Epstein-barr viral (EbV) infection. A number of cases have been positive when tested for 
EbV by EbER in-situ hybridization or dnA analysis. The majority of the EbV-positive cases have 
occurred in children or young adults. The significance of this association is still unclear. in a large 
study of thymic carcinoma cases, including lymphoepithelioma-like carcinoma, no case of EbV-
positive tumor  was recognized. The author concluded that since most reported cases of EbV-
associated tumors occur in young people, an age period when patients are most susceptible to 
EbV infection, the EbV may simply be an innocent bystander rather than having any pathogenetic 
implications. There is also an unusual case reported in the literature of lymphoepithelioma-
like carcinoma of the thymus with focal neuroblastomatous differentiation demonstrated by 
ultrastructural examination. Poorly-differentiated nonkeratinizing squamous cell carcinoma is a 
highly aggressive tumor with a mean survival time of approximately 18 months
As already mentioned, virtually all histotypes have been described in anecdotal cases usually in 
miniseries or compilation collected over very long period of time. An in-depth analysis may be found 
in current textbooks of surgical pathology and in recent reference papers. A summarized list of some 
of these microscopic entities is provided below, reminding again that clinicopathologic correlation 
is essential to make the correct diagnosis, i.e. rule out a metastatic tumor from another malignancy 
before considering the lesion as primary in thymus.  
Mucoepidermoid carcinoma (MeC). it is characterized by the intimate admixture of squamous and 
mucinous components. MEC of thymus is virtually indistinguishable from its counterpart in the 
salivary glands and other organs. Although initially believed to represent low-grade carcinomas of 
the thymus, poorly-differentiated and widely invasive cases with a much more aggressive course 
have now been documented. Approximately 20 cases have been reported so far in the literature. 
Secondary cystic changes are relatively frequent and may be seen in almost half of the cases; they will 
manifest radiographically as multicystic masses on chest CT scans. Multiple multilocular structures of 
varying sizes filled with mucinous material are recognized macroscopically. histologically the tumors 
can display either a well-differentiated, low-grade morphology or features of high-grade, poorly-
differentiated MEC. 
Clear cell carcinoma (CCC) of the thymus. CCC of thymus is a rare variant characterized by cells with 
abundant optically clear cytoplasm. less than 15 cases have been reported so far in the literature. 
These tumors are usually regarded as a high-grade variant of thymic carcinoma:  aggressive course 
is common, being characterized by massive local recurrence with infiltration of adjacent organs and 
distant metastases. A  broad range of cytologic features was noted, from uniform clear cells with 
minimal atypia, to large, pleomorphic tumor cells with prominent nucleoli. in some cases, transitions 
of the clear cells with areas of conventional squamous cell carcinoma was documented. Cytoplasmic 
glycogen was often demonstrated 
Basaloid carcinoma of the thymus (BCt). bCT is another rare variant characterized by haphazardly arranged 
cords and islands of small, round to oval tumor cells characterized by peripheral palisading of nuclei 
recalling basal cell carcinomas of the skin. Cystic changes are common in bCT either as remnants 
of an acquired multilocular thymic cyst or secondary to cystic degeneration of the tumor itself. The 
overriding characteristic is the basaloid arrangement of nuclei at the periphery of the tumor cell 
islands. Mitotic figures are numerous and apoptotic cells can frequently be seen scattered throughout. 
Areas of necrosis are rare. foci of squamous differentiation can also be occasionally identified. 
Carcinosarcoma. This is a rare, biphasic thymic neoplasm characterized by clinical aggressiveness; 
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areas of epithelial differentiation (i.e., carcinoma) and areas composed of truly sarcomatous elements 
are observed microscopically. The epithelial component can be squamoid, adenocarcinomatous, or poorly 
differentiated large cell or anaplastic. The term “sarcomatoid carcinoma” applied to these tumors in the 
past is a misnomer since they do not simply resemble a sarcoma, but actually contain true sarcomatous 
areas as part of their cellular constituents. 
A differential diagnosis is with synovial sarcoma of the anterior mediastinum. Microscopically, synovial 
sarcoma is composed of a monotonous spindle cell proliferation admixed with scattered glandular 
elements. unlike carcinosarcoma, both the spindle cell elements as well as the glandular component will 
show positivity for cytokeratin and EMA. in questionable cases, demonstration of the fusion product for the 
X:18 translocation will be of help in establishing the diagnosis of synovial sarcoma.
Papillary carcinoma, adenosquamous, desmoplastic and giant cell carcinoma and adenocarcinoma of 
the thymus, mucinous and non-mucinous subtypes, nut midline carcinoma with t(15;19) chromosomal 
translocation are very rare and only a few cases have been reported 
Role of Immunohistochemistry
A series of markers have been studied in an attempt to separate thymic carcinoma from thymoma, and 
thymic carcinoma from a metastatic tumor, however little actual progress has been made in this regard and 
much of the available data has been contradictory or inconclusive. The common minimum denominator 
for these tumors is the expression of keratins in the tumor cells. Some studies have also shown increased 
expression of EMA in thymic carcinoma as opposed to thymoma. initial studies of Cd5, Cd70 and Cd117 
seemed very promising in that it was proposed that detection of any of these markers may be used  as 
positive proof to support the diagnosis of primary thymic carcinoma yet further studies have demonstrated 
that a significant proportion of thymic carcinoma are no-reactive with any of these antibodies. in addition, 
numerous extra-thymic neoplasms may be positive for these markers. Expression of c-kit (Cd117) has 
attracted investigators as long as strong staining has been noted in squamous cell carcinoma of the thymus 
and this marker has been negative in the majority of the cases studied of thymoma and extra thymic 
squamous cell carcinomas. Yet, additional validating studies are needed.
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Cases for slide seminar 
Thoracic and mediastinal pathology
CASE 1.  Mass of the anterior mediastinum in a 37 year-old man complaining 
of shortness of breath.
Diagnosis: basaloid carcinoma of the thymus
selected references
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CASE  2.  Pleural tumor in a 39 year-old man presenting with chest pain, shortness 
of breath, general discomfort
Diagnosis: Synovial sarcoma of pleura
selected references
-  Aubry MC, bridge JA, Wickert R, et al. Primary monophasic synovial sarcoma of the pleura: five cases confirmed by the presence of SYT-SSX fusion 
transcript. Am J Surg Pathol. 2001;25:776-781.
-  begueret h, galateau-Salle f, guillou l, et al. Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from 
the french Sarcoma group and the Mesopath group. Am J Surg Pathol. 2005;29:339-346.
-  Colwell AS, d’Cunha J, Vargas SO, et al. Synovial sarcoma of the pleura: a clinical and pathologic study of three cases. J Thorac Cardiovasc Surg. 
2002;124:828-832.
-  Essary lR, Vargas SO, fletcher Cd. Primary pleuropulmonary synovial sarcoma: reappraisal of a recently described anatomic subset. Cancer. 
2002;94:459-469.
-  fisher C. Synovial sarcoma. Ann diagn Pathol. 1998;2:401-421.
-  fisher C, Montgomery E, healy V. Calponin and h-caldesmon expression in synovial sarcoma; the use of calponin in diagnosis. histopathology. 
2003;42:588-593.
-  hartel Ph, fanburg-Smith JC, frazier AA, et al. Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and 
comparison with five prior series. Mod Pathol. 2007;20:760-769.
-  Miettinen M. Modern soft tissue pathology : tumors and non-neoplastic conditions. Cambridge ; new York: Cambridge university Press; 2010.
-  Miettinen M, limon J, niezabitowski A, et al. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities 
and differences with malignant mesothelioma. Am J Surg Pathol. 2001;25:610-617.
-  Morrison C, Wakely PE, Jr., Ashman CJ, et al. Cystic synovial sarcoma. Ann diagn Pathol. 2001;5:48-56.
-  Olsen Sh, Thomas dg, lucas dR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath 
tumor, and Ewing sarcoma. Mod Pathol. 2006;19:659-668.
-  Spillane AJ, A’hern R, Judson iR, et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18:3794-
3803.
-  Spurrell El, fisher C, Thomas JM, et al. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden 
hospital. Ann Oncol. 2005;16:437-444.
-  Suster S, Moran CA. Primary synovial sarcomas of the mediastinum: a clinicopathologic, immunohistochemical, and ultrastructural study of 15 
cases. Am J Surg Pathol. 2005;29:569-578.
-  van de Rijn M, barr fg, Xiong Qb, et al. Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features. 
Am J Surg Pathol. 1999;23:106-112.
117
CASE 3. Incidental pleural mass discovered in a 78 year-old man
Diagnosis: Solitary fibrous tumor
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CASE 4.  Mass of posterior mediastinum growing within the costo-vertebral angle 
in a 32 year-old man
Diagnosis: Malignant (low-grade) peripheral nerve sheath tumor
selected references
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CASE 5.  Mass biopsy fragments in a 69 year-old man with diffuse pleural 
thickening and clinical diagnosis of mesothelioma
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Diagnosis: Metastatic melanoma
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Immunotherapy on the treatment of advanced melanoma
The immune system has the potential for the destruction of tumors and the long term memory can prevent 
cancer recurrence. it is known that malignant melanoma is an immunogenic tumor for decades. Tumor 
specificity of the immune response is based in the recognition of tumor antigens. but in a majority of cancers 
malignant progression is accompanied by immune suppression that interferes with an effective antitumor 
destruction. One of the negative regulator mechanism is the activation of the cytotoxic T-lymphocyte 
antigen-4 (CTlA-4), a negative regulator of T-cell activation. in consequence, infiltrating T-cells fail to be 
sufficiently activated to result in tumor destruction.
ipilimumab is a novel agent that belongs to a class of immunomodulatory agents which alters the balance 
of the immune system. it is a monoclonal antibody targeting the CTlA-4, so increasing the T lymphocytes 
proliferation and tumor destruction. Phase iii studies with ipilimumab for the first time in the history of 
metastatic melanoma showed significantly increase in progression free survival and overall survival.   
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